

References

Kidney International Supplements (2012) **2**, 124–138; doi:10.1038/kisup.2011.38

1. Chertow GM, Burdick E, Honour M, *et al.* Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. *J Am Soc Nephrol* 2005; **16**: 3365–3370.
2. Hoste EA, Clermont G, Kersten A, *et al.* RIFLE criteria for acute kidney injury are associated with hospital mortality in critically ill patients: a cohort analysis. *Crit Care* 2006; **10**: R73.
3. Lassnig A, Schmidlin D, Mouhieddine M, *et al.* Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. *J Am Soc Nephrol* 2004; **15**: 1597–1605.
4. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. *JAMA* 1996; **275**: 1489–1494.
5. Uchino S, Bellomo R, Goldsmith D, *et al.* An assessment of the RIFLE criteria for acute renal failure in hospitalized patients. *Crit Care Med* 2006; **34**: 1913–1917.
6. Hoste EA, Kellum JA. Acute renal failure in the critically ill: impact on morbidity and mortality. *Contrib Nephrol* 2004; **144**: 1–11.
7. Uchino S, Kellum JA, Bellomo R, *et al.* Acute renal failure in critically ill patients: a multinational, multicenter study. *JAMA* 2005; **294**: 813–818.
8. Bagshaw SM, Langenberg C, Bellomo R. Urinary biochemistry and microscopy in septic acute renal failure: a systematic review. *Am J Kidney Dis* 2006; **48**: 695–705.
9. Bagshaw SM, Langenberg C, Wan L, *et al.* A systematic review of urinary findings in experimental septic acute renal failure. *Crit Care Med* 2007; **35**: 1592–1598.
10. Shanley PF, Rosen MD, Brezis M, *et al.* Topography of focal proximal tubular necrosis after ischemia with reflow in the rat kidney. *Am J Pathol* 1986; **122**: 462–468.
11. Heyman SN, Brezis M, Epstein FH, *et al.* Effect of glycine and hypertrophy on renal outer medullary hypoxic injury in ischemia reflow and contrast nephropathy. *Am J Kidney Dis* 1992; **19**: 578–586.
12. Rosen S, Heyman SN. Difficulties in understanding human “acute tubular necrosis”: limited data and flawed animal models. *Kidney Int* 2001; **60**: 1220–1224.
13. Brun C, Munck O. Lesions of the kidney in acute renal failure following shock. *Lancet* 1957; **272**: 603–607.
14. Klenzak J, Himmelfarb J. Sepsis and the kidney. *Crit Care Clin* 2005; **21**: 211–222.
15. Lameire N. The pathophysiology of acute renal failure. *Crit Care Clin* 2005; **21**: 197–210.
16. Eknoyan G. Emergence of the concept of acute renal failure. *Am J Nephrol* 2002; **22**: 225–230.
17. Davies F, Weldon R. A contribution to the study of “war nephritis”. *Lancet* 1917; **ii**: 118–120.
18. Bywaters EGL, Beall D. Crush injuries with impairment of renal function. *BMJ* 1947; **1**: 427–432.
19. Kellum JA, Levin N, Bouman C, *et al.* Developing a consensus classification system for acute renal failure. *Curr Opin Crit Care* 2002; **8**: 509–514.
20. Brivet FG, Kleinknecht DJ, Loirat P, *et al.* Acute renal failure in intensive care units—causes, outcome, and prognostic factors of hospital mortality; a prospective, multicenter study. French Study Group on Acute Renal Failure. *Crit Care Med* 1996; **24**: 192–198.
21. Liano F, Pascual J. Epidemiology of acute renal failure: a prospective, multicenter, community-based study. Madrid Acute Renal Failure Study Group. *Kidney Int* 1996; **50**: 811–818.
22. Bellomo R, Ronco C, Kellum JA, *et al.* Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. *Crit Care* 2004; **8**: R204–212.
23. Mehta RL, Kellum JA, Shah SV, *et al.* Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. *Crit Care* 2007; **11**: R31.
24. Levy MM, Macias WL, Vincent JL, *et al.* Early changes in organ function predict eventual survival in severe sepsis. *Crit Care Med* 2005; **33**: 2194–2201.
25. Bagshaw SM, George C, Dinu I, *et al.* A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients. *Nephrol Dial Transplant* 2008; **23**: 1203–1210.
26. Kellum JA, Bellomo R, Ronco C. Classification of acute kidney injury using RIFLE: What’s the purpose? *Crit Care Med* 2007; **35**: 1983–1984.
27. Ricci Z, Cruz D, Ronco C. The RIFLE criteria and mortality in acute kidney injury: A systematic review. *Kidney Int* 2008; **73**: 538–546.
28. Thakar CV, Christianson A, Freyberg R, *et al.* Incidence and outcomes of acute kidney injury in intensive care units: a Veterans Administration study. *Crit Care Med* 2009; **37**: 2552–2558.
29. Joannidis M, Metnitz B, Bauer P, *et al.* Acute kidney injury in critically ill patients classified by AKIN versus RIFLE using the SAPS 3 database. *Intensive Care Med* 2009; **35**: 1692–1702.
30. Ostermann M, Chang RW. Acute kidney injury in the intensive care unit according to RIFLE. *Crit Care Med* 2007; **35**: 1837–1843.
31. Ali T, Khan I, Simpson W, *et al.* Incidence and outcomes in acute kidney injury: a comprehensive population-based study. *J Am Soc Nephrol* 2007; **18**: 1292–1298.
32. Akcan-Arikan A, Zappitelli M, Loftis LL, *et al.* Modified RIFLE criteria in critically ill children with acute kidney injury. *Kidney Int* 2007; **71**: 1028–1035.
33. Hackworth LA, Wen X, Clermont G, *et al.* Hospital versus community-acquired acute kidney injury in the critically ill: differences in epidemiology (abstr). *J Am Soc Nephrol* 2009; **20**: 115A.
34. Cerda J, Bagga A, Kher V, *et al.* The contrasting characteristics of acute kidney injury in developed and developing countries. *Nat Clin Pract Nephrol* 2008; **4**: 138–153.
35. Cerda J, Lameire N, Eggers P, *et al.* Epidemiology of acute kidney injury. *Clin J Am Soc Nephrol* 2008; **3**: 881–886.
36. *Institute of Medicine. Crossing the Quality Chasm: a New Health System for the 21st Century.* National Academy Press: Washington, DC, 2001.
37. Eknoyan G. Are global nephrology guidelines feasible? *Nat Clin Pract Nephrol* 2008; **4**: 521.
38. Eknoyan G, Lameire N, Barsoum R, *et al.* The burden of kidney disease: improving global outcomes. *Kidney Int* 2004; **66**: 1310–1314.
39. Levin A, Stevens LA. Executing change in the management of chronic kidney disease: perspectives on guidelines and practice. *Med Clin North Am* 2005; **89**: 701–709.
40. Atkins D, Best D, Briss PA, *et al.* Grading quality of evidence and strength of recommendations. *BMJ* 2004; **328**: 1490.
41. Uhlig K, Macleod A, Craig J, *et al.* Grading evidence and recommendations for clinical practice guidelines in nephrology. A position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2006; **70**: 2058–2065.
42. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis* 2002; **39** (2 Suppl 1): S1–266.
43. Levey AS, Eckardt KU, Tsukamoto Y, *et al.* Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). *Kidney Int* 2005; **67**: 2089–2100.
44. Levey AS, de Jong PE, Coresh J, *et al.* The definition, classification and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. *Kidney Int* 2011; **80**: 17–28.
45. Murray PT, Devarajan P, Levey AS, *et al.* A framework and key research questions in AKI diagnosis and staging in different environments. *Clin J Am Soc Nephrol* 2008; **3**: 864–868.
46. Endre ZH. Acute kidney injury: definitions and new paradigms. *Adv Chronic Kidney Dis* 2008; **15**: 213–221.
47. Amdur RL, Chawla LS, Amodeo S, *et al.* Outcomes following diagnosis of acute renal failure in U.S. veterans: focus on acute tubular necrosis. *Kidney Int* 2009; **76**: 1089–1097.
48. Coca SG, Yusuf B, Shlipak MG, *et al.* Long-term risk of mortality and other adverse outcomes after acute kidney injury: a systematic review and meta-analysis. *Am J Kidney Dis* 2009; **53**: 961–973.
49. Wald R, Quinn RR, Luo J, *et al.* Chronic dialysis and death among survivors of acute kidney injury requiring dialysis. *JAMA* 2009; **302**: 1179–1185.
50. Harel Z, Chan CT. Predicting and preventing acute kidney injury after cardiac surgery. *Curr Opin Nephrol Hypertens* 2008; **17**: 624–628.
51. Reddy VG. Prevention of postoperative acute renal failure. *J Postgrad Med* 2002; **48**: 64–70.

52. Venkataraman R. Can we prevent acute kidney injury? *Crit Care Med* 2008; **36**: S166–171.
53. Stewart J, Findlay G, Smith N, *et al.* Adding Insult to Injury: A review of the care of patients who died in hospital with a primary diagnosis of acute kidney injury (acute renal failure). National Confidential Enquiry into Patient Outcome and Death: London, UK, 2009.
54. Bell M, Liljestam E, Granath E, *et al.* Optimal follow-up time after continuous renal replacement therapy in actual renal failure patients stratified with the RIFLE criteria. *Nephrol Dial Transplant* 2005; **20**: 354–360.
55. Cruz DN, Bolgan I, Perazella MA, *et al.* North East Italian Prospective Hospital Renal Outcome Survey on Acute Kidney Injury (NEIPHROS-AKI): targeting the problem with the RIFLE Criteria. *Clin J Am Soc Nephrol* 2007; **2**: 418–425.
56. Perez-Valdivieso JR, Bes-Rastrollo M, Monedero P, *et al.* Prognosis and serum creatinine levels in acute renal failure at the time of nephrology consultation: an observational cohort study. *BMC Nephrol* 2007; **8**: 14.
57. Kuitunen A, Vento A, Suojaranta-Ylinen R, *et al.* Acute renal failure after cardiac surgery: evaluation of the RIFLE classification. *Ann Thorac Surg* 2006; **81**: 542–546.
58. Coca SG, Bauling P, Schiffner T, *et al.* Contribution of acute kidney injury toward morbidity and mortality in burns: a contemporary analysis. *Am J Kidney Dis* 2007; **49**: 517–523.
59. Arnaoutakis GJ, Bihorac A, Martin TD, *et al.* RIFLE criteria for acute kidney injury in aortic arch surgery. *J Thorac Cardiovasc Surg* 2007; **134**: 1554–1560; discussion 1560–1551.
60. Abosaif NY, Tolba YA, Heap M, *et al.* The outcome of acute renal failure in the intensive care unit according to RIFLE: model application, sensitivity, and predictability. *Am J Kidney Dis* 2005; **46**: 1038–1048.
61. Maccariello E, Soares M, Valente C, *et al.* RIFLE classification in patients with acute kidney injury in need of renal replacement therapy. *Intensive Care Med* 2007; **33**: 597–605.
62. Jenq CC, Tsai MH, Tian YC, *et al.* RIFLE classification can predict short-term prognosis in critically ill cirrhotic patients. *Intensive Care Med* 2007; **33**: 1921–1930.
63. Tallgren M, Niemi T, Poyhia R, *et al.* Acute renal injury and dysfunction following elective abdominal aortic surgery. *Eur J Vasc Endovasc Surg* 2007; **33**: 550–555.
64. Zavada J, Hoste E, Cartin-Ceba R, *et al.* A comparison of three methods to estimate baseline creatinine for RIFLE classification. *Nephrol Dial Transplant* 2010; **25**: 3911–3918.
65. Macedo E, Bouchard J, Soroko SH, *et al.* Fluid accumulation, recognition and staging of acute kidney injury in critically-ill patients. *Crit Care* 2010; **14**: R82.
66. Doi K, Yuen PS, Eisner C, *et al.* Reduced production of creatinine limits its use as marker of kidney injury in sepsis. *J Am Soc Nephrol* 2009; **20**: 1217–1221.
67. Levey AS, Coresh J, Greene T, *et al.* Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. *Ann Intern Med* 2006; **145**: 247–254.
68. Stevens LA, Coresh J, Feldman HI, *et al.* Evaluation of the modification of diet in renal disease study equation in a large diverse population. *J Am Soc Nephrol* 2007; **18**: 2749–2757.
69. Emamian SA, Nielsen MB, Pedersen JF, *et al.* Kidney dimensions at sonography: correlation with age, sex, and habitus in 665 adult volunteers. *AJR Am J Roentgenol* 1993; **160**: 83–86.
70. Bellomo R, Wan L, May CN. Vasoactive drugs and acute renal failure. In: Ronco C, Bellomo R, Kellum J (eds). *Critical Care Nephrology*, 2nd Edn. Saunders Elsevier: Philadelphia, PA, 2009, pp 416–419.
71. Bouchard J, Mehta RL. Fluid balance issues in the critically ill patient. In: Ronco C, Costanzo MR, Bellomo R, Maisel A (eds). *Fluid Overload: Diagnosis and Management*. S Karger AG: Basel, Switzerland, 2010, pp 69–78.
72. Finfer S, Jones DA. Crystalloids and colloids. In: Ronco C, Bellomo R, Kellum J (eds). *Critical Care Nephrology*, 2nd Edn. Saunders Elsevier: Philadelphia, PA, 2009, pp 571–575.
73. Holmes CL, Walley KR. Shock. In: Murray PT, Brady HR, Hall JB (eds). *Intensive Care in Nephrology*. Taylor & Francis: New York, NY, 2006, pp 1–18.
74. Levine JS, Iglesias JI. Diuretic use and fluid management. In: Murray PT, Brady HR, Hall JB (eds). *Intensive Care in Nephrology*. Taylor & Francis: New York, NY, 2006, pp 315–337.
75. McDermott G, Neligan PJ. What vasopressor agent should be used in the septic patient? In: Deutschman CS, Neligan PJ (eds). *Evidence-Based Practice of Critical Care*. Saunders: Philadelphia, PA, 2010, pp 206–211.
76. Neligan PJ, Fanning N. What is the best way to fluid-resuscitate a patient with sepsis? In: Deutschman CS, Neligan PJ (eds). *Evidence-Based Practice of Critical Care*. Saunders: Philadelphia, PA, 2010, pp 198–205.
77. Polanco PM, Pinsky MR. Hemodynamic monitoring in the intensive care unit. In: Ronco C, Bellomo R, Kellum J (eds). *Critical Care Nephrology*, 2nd Edn. Saunders Elsevier: Philadelphia, PA, 2009, pp 37–45.
78. Prowle JR, Bellomo R. Continuous renal replacement therapy: recent advances and future research. *Nat Rev Nephrol* 2010; **6**: 521–529.
79. Schetz M. Assessment of volume status. In: Ronco C, Bellomo R, Kellum J (eds). *Critical Care Nephrology*, 2nd Edn. Saunders Elsevier: Philadelphia, PA, 2009, pp 499–504.
80. Venkataraman R, Kellum JA. Principles of fluid therapy. In: Ronco C, Bellomo R, Kellum J (eds). *Critical Care Nephrology*, 2nd Edn. Saunders Elsevier: Philadelphia, PA, 2009, pp 568–571.
81. Wajanaponsan N, Pinsky MR. Monitoring and management of systemic hemodynamics. In: Jorres A, Ronco C, Kellum JA (eds). *Management of Acute Kidney Problems*, 1st Edn. Springer: New York, NY, 2010, pp 147–154.
82. Himmelfarb J, Joannidis M, Molitoris B, *et al.* Evaluation and initial management of acute kidney injury. *Clin J Am Soc Nephrol* 2008; **3**: 962–967.
83. Bouchard J, Soroko SB, Chertow GM, *et al.* Fluid accumulation, survival and recovery of kidney function in critically ill patients with acute kidney injury. *Kidney Int* 2009; **76**: 422–427.
84. Payen D, de Pont AC, Sakr Y, *et al.* A positive fluid balance is associated with a worse outcome in patients with acute renal failure. *Crit Care* 2008; **12**: R74.
85. Vincent JL. Relevance of albumin in modern critical care medicine. *Best Pract Res Clin Anaesthesiol* 2009; **23**: 183–191.
86. Finfer S, Bellomo R, Boyce N, *et al.* A comparison of albumin and saline for fluid resuscitation in the intensive care unit. *N Engl J Med* 2004; **350**: 2247–2256.
87. Ertmer C, Rehberg S, Van Aken H, *et al.* Relevance of non-albumin colloids in intensive care medicine. *Best Pract Res Clin Anaesthesiol* 2009; **23**: 193–212.
88. McMahon BA, Murray PT. Urinary liver fatty acid-binding protein: another novel biomarker of acute kidney injury. *Kidney Int* 2010; **77**: 657–659.
89. Dickenmann M, Oettl T, Mihatsch MJ. Osmotic nephrosis: acute kidney injury with accumulation of proximal tubular lysosomes due to administration of exogenous solutes. *Am J Kidney Dis* 2008; **51**: 491–503.
90. de Saint-Aurin RG, Kloeckner M, Annane D. Crystalloids versus colloids for fluid resuscitation in critically-ill patients. *Acta Clin Belg Suppl* 2007; **412**–416.
91. Vincent JL. Fluid resuscitation: colloids vs crystalloids. *Acta Clin Belg Suppl* 2007; **408**–411.
92. Schortgen F, Lacherade JC, Bruneel F, *et al.* Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. *Lancet* 2001; **357**: 911–916.
93. Brunkhorst FM, Engel C, Bloos F, *et al.* Intensive insulin therapy and pentastarch resuscitation in severe sepsis. *N Engl J Med* 2008; **358**: 125–139.
94. Eisenbach C, Schonfeld AH, Vogt N, *et al.* Pharmacodynamics and organ storage of hydroxyethyl starch in acute hemodilution in pigs: influence of molecular weight and degree of substitution. *Intensive Care Med* 2007; **33**: 1637–1644.
95. Thomas G, Balk EM, Jaber BL. Effect of intensive insulin therapy and pentastarch resuscitation on acute kidney injury in severe sepsis. *Am J Kidney Dis* 2008; **52**: 13–17.
96. Wiedermann CJ. Systematic review of randomized clinical trials on the use of hydroxyethyl starch for fluid management in sepsis. *BMC Emerg Med* 2008; **8**: 1.
97. Sakr Y, Payen D, Reinhart K, *et al.* Effects of hydroxyethyl starch administration on renal function in critically ill patients. *Br J Anaesth* 2007; **98**: 216–224.
98. Perel P, Roberts I, Pearson M. Colloids versus crystalloids for fluid resuscitation in critically ill patients. *Cochrane Database Syst Rev* 2007; **4**: CD000567.
99. Schortgen F, Brochard L. Colloid-induced kidney injury: experimental evidence may help to understand mechanisms. *Crit Care* 2009; **13**: 130.
100. Magder S, Potter BJ, Varennes BD, *et al.* Fluids after cardiac surgery: a pilot study of the use of colloids versus crystalloids. *Crit Care Med* 2010; **38**: 2117–2124.
101. Wiedermann CJ, Duzendorfer S, Gaioni LU, *et al.* Hyperoncotic colloids and acute kidney injury: a meta-analysis of randomized trials. *Crit Care* 2010; **14**: R191.
102. Prowle JR, Bellomo R. Fluid administration and the kidney. *Curr Opin Crit Care* 2010; **16**: 332–336.
103. Kaplan LJ, Kellum JA. Fluids, pH, ions and electrolytes. *Curr Opin Crit Care* 2010; **16**: 323–331.
104. Karlsson S, Varpula M, Ruokonen E, *et al.* Incidence, treatment, and outcome of severe sepsis in ICU-treated adults in Finland: the Finnsepsis study. *Intensive Care Med* 2007; **33**: 435–443.

105. Bellomo R, Wan L, May C. Vasoactive drugs and acute kidney injury. *Crit Care Med* 2008; **36**: S179–186.
106. Redl-Wenzl EM, Armbruster C, Edelmann G, et al. The effects of norepinephrine on hemodynamics and renal function in severe septic shock states. *Intensive Care Med* 1993; **19**: 151–154.
107. Albanese J, Leone M, Delmas A, et al. Terlipressin or norepinephrine in hyperdynamic septic shock: a prospective, randomized study. *Crit Care Med* 2005; **33**: 1897–1902.
108. Lauzier F, Levy B, Lamarre P, et al. Vasopressin or norepinephrine in early hyperdynamic septic shock: a randomized clinical trial. *Intensive Care Med* 2006; **32**: 1782–1789.
109. De Backer D, Biston P, Devriendt J, et al. Comparison of dopamine and norepinephrine in the treatment of shock. *N Engl J Med* 2010; **362**: 779–789.
110. Delmas A, Leone M, Rousseau S, et al. Clinical review: Vasopressin and terlipressin in septic shock patients. *Crit Care* 2005; **9**: 212–222.
111. Russell JA, Walley KR, Singer J, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. *N Engl J Med* 2008; **358**: 877–887.
112. Gordon AC, Russell JA, Walley KR, et al. The effects of vasopressin on acute kidney injury in septic shock. *Intensive Care Med* 2010; **36**: 83–91.
113. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. *Crit Care Med* 2008; **36**: 296–327.
114. Dellinger RP, Carlet JM, Masur H, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. *Crit Care Med* 2004; **32**: 858–873.
115. Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med* 2001; **345**: 1368–1377.
116. Mikkelsen ME, Miliades AN, Gaieski DF, et al. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. *Crit Care Med* 2009; **37**: 1670–1677.
117. Phua J, Koay ES, Lee KH. Lactate, procalcitonin, and amino-terminal pro-B-type natriuretic peptide versus cytokine measurements and clinical severity scores for prognostication in septic shock. *Shock* 2008; **29**: 328–333.
118. Jones AE, Focht A, Horton JM, et al. Prospective external validation of the clinical effectiveness of an emergency department-based early goal-directed therapy protocol for severe sepsis and septic shock. *Chest* 2007; **132**: 425–432.
119. Lin SM, Huang CD, Lin HC, et al. A modified goal-directed protocol improves clinical outcomes in intensive care unit patients with septic shock: a randomized controlled trial. *Shock* 2006; **26**: 551–557.
120. Nguyen HB, Corbett SW, Menes K, et al. Early goal-directed therapy, corticosteroid, and recombinant human activated protein C for the treatment of severe sepsis and septic shock in the emergency department. *Acad Emerg Med* 2006; **13**: 109–113.
121. Rhodes A, Bennett ED. Early goal-directed therapy: an evidence-based review. *Crit Care Med* 2004; **32**: S448–450.
122. Rivers EP, Coba V, Whitmill M. Early goal-directed therapy in severe sepsis and septic shock: a contemporary review of the literature. *Curr Opin Anaesthesiol* 2008; **21**: 128–140.
123. Ho BC, Bellomo R, McGain F, et al. The incidence and outcome of septic shock patients in the absence of early-goal directed therapy. *Crit Care* 2006; **10**: R80.
124. Donati A, Loggi S, Preiser JC, et al. Goal-directed intraoperative therapy reduces morbidity and length of hospital stay in high-risk surgical patients. *Chest* 2007; **132**: 1817–1824.
125. Lobo SM, Salgado PF, Castillo VG, et al. Effects of maximizing oxygen delivery on morbidity and mortality in high-risk surgical patients. *Crit Care Med* 2000; **28**: 3396–3404.
126. Shoemaker WC, Appel PL, Kram HB, et al. Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. *Chest* 1988; **94**: 1176–1186.
127. Brienza N, Giglio MT, Marucci M, et al. Does perioperative hemodynamic optimization protect renal function in surgical patients? A meta-analytic study. *Crit Care Med* 2009; **37**: 2079–2090.
128. Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. SvO₂ Collaborative Group. *N Engl J Med* 1995; **333**: 1025–1032.
129. Hayes MA, Timmins AC, Yau EH, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. *N Engl J Med* 1994; **330**: 1717–1722.
130. Section VII. Acute renal failure. In: Schrier RW (ed). *Diseases of the Kidney and Urinary Tract*, 8th Edn, vol. 2. Lippincott Williams & Wilkins: Philadelphia, PA, 2007, pp 930–1207.
131. Part VI. Diagnosis and management of specific disorders. In: Jorres A, Ronco C, Kellum JA (eds). *Management of Acute Kidney Problems*, 1st Edn. Springer: New York, NY, 2010, pp 269–467.
132. Murugan R, Kellum JA. Acute kidney injury: what's the prognosis? *Nat Rev Nephrol* 2011; **7**: 209–217.
133. Siew ED, Himmelfarb J. Metabolic and nutritional complications of acute kidney injury. In: Himmelfarb J, Sayegh MH (eds). *Chronic Kidney Disease, Dialysis, and Transplantation. A Companion to Brenner and Rector's The Kidney*, 3rd Edn: London, UK, 2011, pp 654–667.
134. Van Cromphaut SJ. Hyperglycaemia as part of the stress response: the underlying mechanisms. *Best Pract Res Clin Anaesthesiol* 2009; **23**: 375–386.
135. Kosiborod M, Inzucchi SE, Goyal A, et al. Relationship between spontaneous and iatrogenic hypoglycemia and mortality in patients hospitalized with acute myocardial infarction. *JAMA* 2009; **301**: 1556–1564.
136. Kosiborod M, Rathore SS, Inzucchi SE, et al. Admission glucose and mortality in elderly patients hospitalized with acute myocardial infarction: implications for patients with and without recognized diabetes. *Circulation* 2005; **111**: 3078–3086.
137. Inzucchi SE, Siegel MD. Glucose control in the ICU—how tight is too tight? *N Engl J Med* 2009; **360**: 1346–1349.
138. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. *N Engl J Med* 2001; **345**: 1359–1367.
139. Palevsky PM, Murray PT. Acute kidney injury and critical care nephrology. *NephSAP* 2006; **5**(2): 72–120.
140. Van den Berghe G, Wouters PJ, Kesteloot K, et al. Analysis of healthcare resource utilization with intensive insulin therapy in critically ill patients. *Crit Care Med* 2006; **34**: 612–616.
141. Van den Berghe G, Wilmer A, Hermans G, et al. Intensive insulin therapy in the medical ICU. *N Engl J Med* 2006; **354**: 449–461.
142. Schetz M, Vanhorebeek I, Wouters PJ, et al. Tight blood glucose control is renoprotective in critically ill patients. *J Am Soc Nephrol* 2008; **19**: 571–578.
143. Gandhi GY, Nuttall GA, Abel MD, et al. Intensive intraoperative insulin therapy versus conventional glucose management during cardiac surgery: a randomized trial. *Ann Intern Med* 2007; **146**: 233–243.
144. Mangano CM, Diamondstone LS, Ramsay JG, et al. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. *Ann Intern Med* 1998; **128**: 194–203.
145. Thomas G, Rojas MC, Epstein SK, et al. Insulin therapy and acute kidney injury in critically ill patients: a systematic review. *Nephrol Dial Transplant* 2007; **22**: 2849–2855.
146. Wiener RS, Wiener DC, Larson RJ. Benefits and risks of tight glucose control in critically ill adults: a meta-analysis. *JAMA* 2008; **300**: 933–944.
147. Bellomo R. Does intensive insulin therapy protect renal function in critically ill patients? *Nat Clin Pract Nephrol* 2008; **4**: 412–413.
148. Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. *N Engl J Med* 2009; **360**: 1283–1297.
149. Van den Berghe G, Schetz M, Vlasselaers D, et al. Clinical review: Intensive insulin therapy in critically ill patients: NICE-SUGAR or Leuven blood glucose target? *J Clin Endocrinol Metab* 2009; **94**: 3163–3170.
150. Griesdale DE, de Souza RJ, van Dam RM, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. *CMAJ* 2009; **180**: 821–827.
151. Fiaccadori E, Lombardi M, Leonardi S, et al. Prevalence and clinical outcome associated with preexisting malnutrition in acute renal failure: a prospective cohort study. *J Am Soc Nephrol* 1999; **10**: 581–593.
152. Btaiche IF, Mohammad RA, Alaniz C, et al. Amino Acid requirements in critically ill patients with acute kidney injury treated with continuous renal replacement therapy. *Pharmacotherapy* 2008; **28**: 600–613.
153. Cano N, Fiaccadori E, Tesinsky P, et al. ESPEN Guidelines on Enteral Nutrition: Adult renal failure. *Clin Nutr* 2006; **25**: 295–310.
154. Druml W. Nutritional management of acute renal failure. *J Ren Nutr* 2005; **15**: 63–70.
155. McClave SA, Hurt RT. Clinical guidelines and nutrition therapy: better understanding and greater application to patient care. *Crit Care Clin* 2010; **26**: 451–466, viii.
156. McClave SA, Martindale RG, Vanek VW, et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Adult Critically Ill Patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). *JPEN J Parenter Enteral Nutr* 2009; **33**: 277–316.
157. Fiaccadori E, Regolisti G, Cabassi A. Specific nutritional problems in acute kidney injury, treated with non-dialysis and dialytic modalities. *NDT Plus* 2010; **3**: 1–7.
158. Basi S, Pupim LB, Simmons EM, et al. Insulin resistance in critically ill patients with acute renal failure. *Am J Physiol Renal Physiol* 2005; **289**: F259–264.
159. May RC, Clark AS, Goheer MA, et al. Specific defects in insulin-mediated muscle metabolism in acute uremia. *Kidney Int* 1985; **28**: 490–497.

160. Cianciaruso B, Bellizzi V, Napoli R, *et al.* Hepatic uptake and release of glucose, lactate, and amino acids in acutely uremic dogs. *Metabolism* 1991; **40**: 261–269.
161. Druml W, Mitch WE. Metabolic abnormalities in acute renal failure. *Semin Dial* 1996; **9**: 484–490.
162. Schneeweiss B, Graninger W, Stockenhuber F, *et al.* Energy metabolism in acute and chronic renal failure. *Am J Clin Nutr* 1990; **52**: 596–601.
163. Macias WL, Alaka KJ, Murphy MH, *et al.* Impact of the nutritional regimen on protein catabolism and nitrogen balance in patients with acute renal failure. *JPEN J Parenter Enteral Nutr* 1996; **20**: 56–62.
164. Fiaccadori E, Maggiore U, Rotelli C, *et al.* Effects of different energy intakes on nitrogen balance in patients with acute renal failure: a pilot study. *Nephrol Dial Transplant* 2005; **20**: 1976–1980.
165. Fiaccadori E, Cremaschi E. Nutritional assessment and support in acute kidney injury. *Curr Opin Crit Care* 2009; **15**: 474–480.
166. Powell-Tuck J. Nutritional interventions in critical illness. *Proc Nutr Soc* 2007; **66**: 16–24.
167. Scheinkestel CD, Adams F, Mahony L, *et al.* Impact of increasing parenteral protein loads on amino acid levels and balance in critically ill anuric patients on continuous renal replacement therapy. *Nutrition* 2003; **19**: 733–740.
168. Bellomo R, Tan HK, Bhanagiri S, *et al.* High protein intake during continuous hemodiafiltration: impact on amino acids and nitrogen balance. *Int J Artif Organs* 2002; **25**: 261–268.
169. Druml W. Metabolic aspects of continuous renal replacement therapies. *Kidney Int Suppl* 1999; S56–61.
170. Chima CS, Meyer L, Hummel AC, *et al.* Protein catabolic rate in patients with acute renal failure on continuous arteriovenous hemofiltration and total parenteral nutrition. *J Am Soc Nephrol* 1993; **3**: 1516–1521.
171. Leblanc M, Garred LJ, Cardinal J, *et al.* Catabolism in critical illness: estimation from urea nitrogen appearance and creatinine production during continuous renal replacement therapy. *Am J Kidney Dis* 1998; **32**: 444–453.
172. Marshall MR, Golper TA, Shaver MJ, *et al.* Urea kinetics during sustained low-efficiency dialysis in critically ill patients requiring renal replacement therapy. *Am J Kidney Dis* 2002; **39**: 556–570.
173. Salahudeen AK, Kumar V, Madan N, *et al.* Sustained low efficiency dialysis in the continuous mode (C-SLED): dialysis efficacy, clinical outcomes, and survival predictors in critically ill cancer patients. *Clin J Am Soc Nephrol* 2009; **4**: 1338–1346.
174. Barnert J, Dumitrascu D, Neeser G, *et al.* Gastric emptying of a liquid meal in intensive care unit patients (abstr). *Gastroenterology* 1998; **114**: A865.
175. Fiaccadori E, Maggiore U, Clima B, *et al.* Incidence, risk factors, and prognosis of gastrointestinal hemorrhage complicating acute renal failure. *Kidney Int* 2001; **59**: 1510–1519.
176. Metnitz PG, Krenn CG, Steltzer H, *et al.* Effect of acute renal failure requiring renal replacement therapy on outcome in critically ill patients. *Crit Care Med* 2002; **30**: 2051–2058.
177. Scheinkestel CD, Kar L, Marshall K, *et al.* Prospective randomized trial to assess caloric and protein needs of critically ill, anuric, ventilated patients requiring continuous renal replacement therapy. *Nutrition* 2003; **19**: 909–916.
178. Fiaccadori E, Maggiore U, Giacosa R, *et al.* Enteral nutrition in patients with acute renal failure. *Kidney Int* 2004; **65**: 999–1008.
179. Caldwell MD, Kennedy-Caldwell C. Normal nutritional requirements. *Surg Clin North Am* 1981; **61**: 489–507.
180. Zappitelli M, Goldstein SL, Symons JM, *et al.* Protein and calorie prescription for children and young adults receiving continuous renal replacement therapy: a report from the Prospective Pediatric Continuous Renal Replacement Therapy Registry Group. *Crit Care Med* 2008; **36**: 3239–3245.
181. Mehta RL, Pascual MT, Soroko S, *et al.* Diuretics, mortality, and nonrecovery of renal function in acute renal failure. *JAMA* 2002; **288**: 2547–2553.
182. Uchino S, Doig GS, Bellomo R, *et al.* Diuretics and mortality in acute renal failure. *Crit Care Med* 2004; **32**: 1669–1677.
183. Karajala V, Mansour W, Kellum JA. Diuretics in acute kidney injury. *Minerva Anestesiol* 2009; **75**: 251–257.
184. Ponto LL, Schoenwald RD. Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part II). *Clin Pharmacokinet* 1990; **18**: 460–471.
185. Ponto LL, Schoenwald RD. Furosemide (frusemide). A pharmacokinetic/pharmacodynamic review (Part I). *Clin Pharmacokinet* 1990; **18**: 381–408.
186. Ludens JH, Hook JB, Brody MJ, *et al.* Enhancement of renal blood flow by furosemide. *J Pharmacol Exp Ther* 1968; **163**: 456–460.
187. Ludens JH, Williamson HE. Effect of furosemide on renal blood flow in the conscious dog. *Proc Soc Exp Biol Med* 1970; **133**: 513–515.
188. Cantarovich F, Rangoonwala B, Lorenz H, *et al.* High-dose furosemide for established ARF: a prospective, randomized, double-blind, placebo-controlled, multicenter trial. *Am J Kidney Dis* 2004; **44**: 402–409.
189. Lassnigg A, Donner E, Grubhofer G, *et al.* Lack of renoprotective effects of dopamine and furosemide during cardiac surgery. *J Am Soc Nephrol* 2000; **11**: 97–104.
190. Lombardi R, Ferreiro A, Servetto C. Renal function after cardiac surgery: adverse effect of furosemide. *Ren Fail* 2003; **25**: 775–786.
191. Solomon R, Werner C, Mann D, *et al.* Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. *N Engl J Med* 1994; **331**: 1416–1420.
192. Ho KM, Sheridan DJ. Meta-analysis of frusemide to prevent or treat acute renal failure. *BMJ* 2006; **333**: 420.
193. Ho KM, Power BM. Benefits and risks of furosemide in acute kidney injury. *Anaesthesia* 2010; **65**: 283–293.
194. Hager B, Betschart M, Krapp R. Effect of postoperative intravenous loop diuretic on renal function after major surgery. *Schweiz Med Wochenschr* 1996; **126**: 666–673.
195. van der Voort PH, Boerma EC, Koopmans M, *et al.* Furosemide does not improve renal recovery after hemofiltration for acute renal failure in critically ill patients: a double blind randomized controlled trial. *Crit Care Med* 2009; **37**: 533–538.
196. Uchino S, Bellomo R, Morimatsu H, *et al.* Discontinuation of continuous renal replacement therapy: a *post hoc* analysis of a prospective multicenter observational study. *Crit Care Med* 2009; **37**: 2576–2582.
197. Weisberg LS, Kurnik PB, Kurnik BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. *Kidney Int* 1994; **45**: 259–265.
198. Schetz M. Should we use diuretics in acute renal failure? *Best Pract Res Clin Anaesthesiol* 2004; **18**: 75–89.
199. Yallop KG, Sheppard SV, Smith DC. The effect of mannitol on renal function following cardio-pulmonary bypass in patients with normal pre-operative creatinine. *Anaesthesia* 2008; **63**: 576–582.
200. Smith MN, Best D, Sheppard SV, *et al.* The effect of mannitol on renal function after cardiopulmonary bypass in patients with established renal dysfunction. *Anaesthesia* 2008; **63**: 701–704.
201. Schnuelle P, Johannes van der Woude F. Perioperative fluid management in renal transplantation: a narrative review of the literature. *Transpl Int* 2006; **19**: 947–959.
202. van Valenberg PL, Hoitsma AJ, Tiggeler RG, *et al.* Mannitol as an indispensable constituent of an intraoperative hydration protocol for the prevention of acute renal failure after renal cadaveric transplantation. *Transplantation* 1987; **44**: 784–788.
203. Weimar W, Geerlings W, Bijnen AB, *et al.* A controlled study on the effect of mannitol on immediate renal function after cadaver donor kidney transplantation. *Transplantation* 1983; **35**: 99–101.
204. Better OS, Rubinstein I, Winaver JM, *et al.* Mannitol therapy revisited (1940–1997). *Kidney Int* 1997; **52**: 886–894.
205. Sever MS, Vanholder R, Lameire N. Management of crush-related injuries after disasters. *N Engl J Med* 2006; **354**: 1052–1063.
206. Vanholder R, Sever MS, Ereik E, *et al.* Rhabdomyolysis. *J Am Soc Nephrol* 2000; **11**: 1553–1561.
207. Bellomo R, Chapman M, Finfer S, *et al.* Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. *Lancet* 2000; **356**: 2139–2143.
208. Murray PT. Use of dopaminergic agents for renoprotection in the ICU. Yearbook of Intensive Care and Emergency Medicine. Springer-Verlag: Berlin, Germany, 2003: 637–648.
209. Lauschke A, Teichgraber UK, Frei U, *et al.* ‘Low-dose’ dopamine worsens renal perfusion in patients with acute renal failure. *Kidney Int* 2006; **69**: 1669–1674.
210. Kellum JA, M Decker J. Use of dopamine in acute renal failure: a meta-analysis. *Crit Care Med* 2001; **29**: 1526–1531.
211. Marik PE. Low-dose dopamine: a systematic review. *Intensive Care Med* 2002; **28**: 877–883.
212. Friedrich JO, Adhikari N, Herridge MS, *et al.* Meta-analysis: low-dose dopamine increases urine output but does not prevent renal dysfunction or death. *Ann Intern Med* 2005; **142**: 510–524.
213. Murray PT. Fenoldopam: renal-dose dopamine redux? *Crit Care Med* 2006; **34**: 910–911.
214. Cogliati AA, Vellutini R, Nardini A, *et al.* Fenoldopam infusion for renal protection in high-risk cardiac surgery patients: a randomized clinical study. *J Cardiothorac Vasc Anesth* 2007; **21**: 847–850.
215. Landoni G, Biondi-Zoccai GG, Marino G, *et al.* Fenoldopam reduces the need for renal replacement therapy and in-hospital death in cardiovascular surgery: a meta-analysis. *J Cardiothorac Vasc Anesth* 2008; **22**: 27–33.

216. Morelli A, Ricci Z, Bellomo R, *et al.* Prophylactic fenoldopam for renal protection in sepsis: a randomized, double-blind, placebo-controlled pilot trial. *Crit Care Med* 2005; **33**: 2451–2456.
217. Aravindan N, Natarajan M, Shaw AD. Fenoldopam inhibits nuclear translocation of nuclear factor kappa B in a rat model of surgical ischemic acute renal failure. *J Cardiothorac Vasc Anesth* 2006; **20**: 179–186.
218. Aravindan N, Samuels J, Riedel B, *et al.* Fenoldopam improves cortico-medullary oxygen delivery and attenuates angiogenesis gene expression in acute ischemic renal injury. *Kidney Blood Press Res* 2006; **29**: 165–174.
219. Kellum JA. Prophylactic fenoldopam for renal protection? No, thank you, not for me—not yet at least. *Crit Care Med* 2005; **33**: 2681–2683.
220. Stone GW, McCullough PA, Tumlin JA, *et al.* Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial. *JAMA* 2003; **290**: 2284–2291.
221. Tumlin JA, Finkel KW, Murray PT, *et al.* Fenoldopam mesylate in early acute tubular necrosis: a randomized, double-blind, placebo-controlled clinical trial. *Am J Kidney Dis* 2005; **46**: 26–34.
222. Brienza N, Malcangi V, Dalfino L, *et al.* A comparison between fenoldopam and low-dose dopamine in early renal dysfunction of critically ill patients. *Crit Care Med* 2006; **34**: 707–714.
223. Landoni G, Biondi-Zoccai GG, Tumlin JA, *et al.* Beneficial impact of fenoldopam in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. *Am J Kidney Dis* 2007; **49**: 56–68.
224. Ricksten SE, Sward K. Atrial natriuretic peptide in acute renal failure. In: Ronco C, Bellomo R, Kellum J (eds). *Critical Care Nephrology*, 2nd Edn. Saunders Elsevier: Philadelphia, PA, 2009, pp 429–433.
225. Vesely DL. Natriuretic peptides and acute renal failure. *Am J Physiol Renal Physiol* 2003; **285**: F167–177.
226. Marin-Grez M, Fleming JT, Steinhausen M. Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. *Nature* 1986; **324**: 473–476.
227. Valsson F, Ricksten SE, Hedner T, *et al.* Effects of atrial natriuretic peptide on renal function after cardiac surgery and in cyclosporine-treated heart transplant recipients. *J Cardiothorac Vasc Anesth* 1994; **8**: 425–430.
228. Ratcliffe PJ, Richardson AJ, Kirby JE, *et al.* Effect of intravenous infusion of atriopeptin 3 on immediate renal allograft function. *Kidney Int* 1991; **39**: 164–168.
229. Sands JM, Neylan JE, Olson RA, *et al.* Atrial natriuretic factor does not improve the outcome of cadaveric renal transplantation. *J Am Soc Nephrol* 1991; **1**: 1081–1086.
230. Kurnik BR, Allgren RL, Genter FC, *et al.* Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. *Am J Kidney Dis* 1998; **31**: 674–680.
231. Allgren RL, Marbury TC, Rahman SN, *et al.* Anaritide in acute tubular necrosis. Auriculin Anaritide Acute Renal Failure Study Group. *N Engl J Med* 1997; **336**: 828–834.
232. Lewis J, Salem MM, Chertow GM, *et al.* Atrial natriuretic factor in oliguric acute renal failure. Anaritide Acute Renal Failure Study Group. *Am J Kidney Dis* 2000; **36**: 767–774.
233. Sward K, Valsson F, Odencrants P, *et al.* Recombinant human atrial natriuretic peptide in ischemic acute renal failure: a randomized placebo-controlled trial. *Crit Care Med* 2004; **32**: 1310–1315.
234. Sward K, Valsson F, Sellgren J, *et al.* Differential effects of human atrial natriuretic peptide and furosemide on glomerular filtration rate and renal oxygen consumption in humans. *Intensive Care Med* 2005; **31**: 79–85.
235. Nigwekar SU, Navaneethan SD, Parikh CR, *et al.* Atrial natriuretic peptide for management of acute kidney injury: a systematic review and meta-analysis. *Clin J Am Soc Nephrol* 2009; **4**: 261–272.
236. Forssmann W, Meyer M, Forssmann K. The renal urodilatin system: clinical implications. *Cardiovasc Res* 2001; **51**: 450–462.
237. Hummel M, Kuhn M, Bub A, *et al.* Urodilatin: a new peptide with beneficial effects in the postoperative therapy of cardiac transplant recipients. *Clin Investig* 1992; **70**: 674–682.
238. Brenner P, Meyer M, Reichenspurner H, *et al.* Significance of prophylactic urodilatin (INN: ularitide) infusion for the prevention of acute renal failure in patients after heart transplantation. *Eur J Med Res* 1995; **1**: 137–143.
239. Sackner-Bernstein JD, Kowalski M, Fox M, *et al.* Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. *JAMA* 2005; **293**: 1900–1905.
240. Sackner-Bernstein JD, Skopicki HA, Aaronson KD. Risk of worsening renal function with nesiritide in patients with acutely decompensated heart failure. *Circulation* 2005; **111**: 1487–1491.
241. Topol EJ. Nesiritide - not verified. *N Engl J Med* 2005; **353**: 113–116.
242. Iglesias JI, DePalma L, Hom D, *et al.* Predictors of mortality in adult patients with congestive heart failure receiving nesiritide—retrospective analysis showing a potential adverse interaction between nesiritide and acute renal dysfunction. *Nephrol Dial Transplant* 2008; **23**: 144–153.
243. Mentzer RM, Jr, Oz MC, Sladen RN, *et al.* Effects of perioperative nesiritide in patients with left ventricular dysfunction undergoing cardiac surgery: the NAPA Trial. *J Am Coll Cardiol* 2007; **49**: 716–726.
244. Ejaz AA, Martin TD, Johnson RJ, *et al.* Prophylactic nesiritide does not prevent dialysis or all-cause mortality in patients undergoing high-risk cardiac surgery. *J Thorac Cardiovasc Surg* 2009; **138**: 959–964.
245. Lingegowda V, Van QC, Shimada M, *et al.* Long-term outcome of patients treated with prophylactic nesiritide for the prevention of acute kidney injury following cardiovascular surgery. *Clin Cardiol* 2010; **33**: 217–221.
246. Hammerman MR. Potential role of growth factors in the prophylaxis and treatment of acute renal failure. *Kidney Int Suppl* 1998; **64**: S19–22.
247. Bernhardt WM, Eckardt KU. Physiological basis for the use of erythropoietin in critically ill patients at risk for acute kidney injury. *Curr Opin Crit Care* 2008; **14**: 621–626.
248. Ding H, Kopple JD, Cohen A, *et al.* Recombinant human insulin-like growth factor-I accelerates recovery and reduces catabolism in rats with ischemic acute renal failure. *J Clin Invest* 1993; **91**: 2281–2287.
249. Friedlaender M, Popovtzer MM, Weiss O, *et al.* Insulin-like growth factor-1 (IGF-1) enhances recovery from HgCl₂-induced acute renal failure: the effects on renal IGF-1, IGF-1 receptor, and IGF-binding protein-1 mRNA. *J Am Soc Nephrol* 1995; **5**: 1782–1791.
250. Miller SB, Martin DR, Kissane J, *et al.* Insulin-like growth factor I accelerates recovery from ischemic acute tubular necrosis in the rat. *Proc Natl Acad Sci U S A* 1992; **89**: 11876–11880.
251. Petrincic D, Reilly JM, Sicard GA, *et al.* Insulin-like growth factor-I attenuates delayed graft function in a canine renal autotransplantation model. *Surgery* 1996; **120**: 221–225; discussion 225–226.
252. Franklin SC, Moulton M, Sicard GA, *et al.* Insulin-like growth factor I preserves renal function postoperatively. *Am J Physiol* 1997; **272**: F257–259.
253. Hirschberg R, Kopple J, Lipsett P, *et al.* Multicenter clinical trial of recombinant human insulin-like growth factor I in patients with acute renal failure. *Kidney Int* 1999; **55**: 2423–2432.
254. Hladunewich MA, Corrigan G, Derby GC, *et al.* A randomized, placebo-controlled trial of IGF-1 for delayed graft function: a human model to study postischemic ARF. *Kidney Int* 2003; **64**: 593–602.
255. Song YR, Lee T, You SJ, *et al.* Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. *Am J Nephrol* 2009; **30**: 253–260.
256. Endre ZH, Walker RJ, Pickering JW, *et al.* Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). *Kidney Int* 2010; **77**: 1020–1030.
257. Karlowicz MG, Adelman RD. Nonoliguric and oliguric acute renal failure in asphyxiated term neonates. *Pediatr Nephrol* 1995; **9**: 718–722.
258. Gouyon JB, Guignard JP. Theophylline prevents the hypoxemia-induced renal hemodynamic changes in rabbits. *Kidney Int* 1988; **33**: 1078–1083.
259. Bakr AF. Prophylactic theophylline to prevent renal dysfunction in newborns exposed to perinatal asphyxia—a study in a developing country. *Pediatr Nephrol* 2005; **20**: 1249–1252.
260. Bhat MA, Shah ZA, Makhdoomi MS, *et al.* Theophylline for renal function in term neonates with perinatal asphyxia: a randomized, placebo-controlled trial. *J Pediatr* 2006; **149**: 180–184.
261. Jenik AG, Ceriani Cernadas JM, Gorenstein A, *et al.* A randomized, double-blind, placebo-controlled trial of the effects of prophylactic theophylline on renal function in term neonates with perinatal asphyxia. *Pediatrics* 2000; **105**: E45.
262. Cattarelli D, Spandrio M, Gasparoni A, *et al.* A randomised, double blind, placebo controlled trial of the effect of theophylline in prevention of vasomotor nephropathy in very preterm neonates with respiratory distress syndrome. *Arch Dis Child Fetal Neonatal Ed* 2006; **91**: F80–84.
263. Gottlieb SS, Brater DC, Thomas I, *et al.* BG9719 (CVT-124), an A1 adenosine receptor antagonist, protects against the decline in renal function observed with diuretic therapy. *Circulation* 2002; **105**: 1348–1353.
264. Givertz MM, Massie BM, Fields TK, *et al.* The effects of KW-3902, an adenosine A1-receptor antagonist, on diuresis and renal function in patients with acute decompensated heart failure and renal impairment or diuretic resistance. *J Am Coll Cardiol* 2007; **50**: 1551–1560.
265. Cotter G, Dittrich HC, Weatherley BD, *et al.* The PROTECT pilot study: a randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. *J Card Fail* 2008; **14**: 631–640.
266. Massie BM, O'Connor CM, Metra M, *et al.* Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. *N Engl J Med* 2010; **363**: 1419–1428.

267. Falagas ME, Kopterides P. Old antibiotics for infections in critically ill patients. *Curr Opin Crit Care* 2007; **13**: 592-597.
268. Rea RS, Capitano B. Optimizing use of aminoglycosides in the critically ill. *Semin Respir Crit Care Med* 2007; **28**: 596-603.
269. Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. *Crit Care Med* 2009; **37**: 840-851.
270. Zahar JR, Rioux C, Girou E, et al. Inappropriate prescribing of aminoglycosides: risk factors and impact of an antibiotic control team. *J Antimicrob Chemother* 2006; **58**: 651-656.
271. Bliziotis IA, Michalopoulos A, Kasiakou SK, et al. Ciprofloxacin vs an aminoglycoside in combination with a beta-lactam for the treatment of febrile neutropenia: a meta-analysis of randomized controlled trials. *Mayo Clin Proc* 2005; **80**: 1146-1156.
272. Falagas ME, Matthaiou DK, Bliziotis IA. The role of aminoglycosides in combination with a beta-lactam for the treatment of bacterial endocarditis: a meta-analysis of comparative trials. *J Antimicrob Chemother* 2006; **57**: 639-647.
273. Falagas ME, Matthaiou DK, Karveli EA, et al. Meta-analysis: randomized controlled trials of clindamycin/aminoglycoside vs. beta-lactam monotherapy for the treatment of intra-abdominal infections. *Aliment Pharmacol Ther* 2007; **25**: 537-556.
274. Glasmacher A, von Lilienfeld-Toal M, Schulte S, et al. An evidence-based evaluation of important aspects of empirical antibiotic therapy in febrile neutropenic patients. *Clin Microbiol Infect* 2005; **11** (Suppl 5): 17-23.
275. Paul M, Benuri-Silbiger I, Soares-Weiser K, et al. Beta lactam monotherapy versus beta lactam-aminoglycoside combination therapy for sepsis in immunocompetent patients: systematic review and meta-analysis of randomised trials. *BMJ* 2004; **328**: 668.
276. Paul M, Silbiger I, Grozinsky S, et al. Beta lactam antibiotic monotherapy versus beta lactam-aminoglycoside antibiotic combination therapy for sepsis. *Cochrane Database Syst Rev* 2006: CD003344.
277. English WP, Williams MD. Should aminoglycoside antibiotics be abandoned? *Am J Surg* 2000; **180**: 512-515; discussion 515-516.
278. Cosgrove SE, Vigliani GA, Fowler VG, Jr., et al. Initial low-dose gentamicin for *Staphylococcus aureus* bacteremia and endocarditis is nephrotoxic. *Clin Infect Dis* 2009; **48**: 713-721.
279. Olaison L, Schadewitz K. Enterococcal endocarditis in Sweden, 1995-1999: can shorter therapy with aminoglycosides be used? *Clin Infect Dis* 2002; **34**: 159-166.
280. Ali BH. Agents ameliorating or augmenting experimental gentamicin nephrotoxicity: some recent research. *Food Chem Toxicol* 2003; **41**: 1447-1452.
281. Bledsoe G, Crickman S, Mao J, et al. Kallikrein/kinin protects against gentamicin-induced nephrotoxicity by inhibition of inflammation and apoptosis. *Nephrol Dial Transplant* 2006; **21**: 624-633.
282. Bledsoe G, Shen B, Yao YY, et al. Role of tissue kallikrein in prevention and recovery of gentamicin-induced renal injury. *Toxicol Sci* 2008; **102**: 433-443.
283. Ekor M, Farombi EO, Emerole GO. Modulation of gentamicin-induced renal dysfunction and injury by the phenolic extract of soybean (Glycine max). *Fundam Clin Pharmacol* 2006; **20**: 263-271.
284. Feldman L, Efrati S, Eviatar E, et al. Gentamicin-induced ototoxicity in hemodialysis patients is ameliorated by N-acetylcysteine. *Kidney Int* 2007; **72**: 359-363.
285. Girtton RA, Sundin DP, Rosenberg ME. Clusterin protects renal tubular epithelial cells from gentamicin-mediated cytotoxicity. *Am J Physiol Renal Physiol* 2002; **282**: F703-709.
286. Horibe T, Matsui H, Tanaka M, et al. Gentamicin binds to the lectin site of calreticulin and inhibits its chaperone activity. *Biochem Biophys Res Commun* 2004; **323**: 281-287.
287. Kaynar K, Gul S, Ersoz S, et al. Amikacin-induced nephropathy: is there any protective way? *Ren Fail* 2007; **29**: 23-27.
288. Martinez-Salgado C, Lopez-Hernandez FJ, Lopez-Novoa JM. Glomerular nephrotoxicity of aminoglycosides. *Toxicol Appl Pharmacol* 2007; **223**: 86-98.
289. Montagut C, Bosch F, Villela L, et al. Aminoglycoside-associated severe renal failure in patients with multiple myeloma treated with thalidomide. *Leuk Lymphoma* 2004; **45**: 1711-1712.
290. Morales AI, Rodriguez-Barbero A, Vicente-Sanchez C, et al. Resveratrol inhibits gentamicin-induced mesangial cell contraction. *Life Sci* 2006; **78**: 2373-2377.
291. Parlakpınar H, Koc M, Polat A, et al. Protective effect of aminoguanidine against nephrotoxicity induced by amikacin in rats. *Urol Res* 2004; **32**: 278-282.
292. Rougier F, Claude D, Maurin M, et al. Aminoglycoside nephrotoxicity. *Curr Drug Targets Infect Disord* 2004; **4**: 153-162.
293. Schmitz C, Hilpert J, Jacobsen C, et al. Megalin deficiency offers protection from renal aminoglycoside accumulation. *J Biol Chem* 2002; **277**: 618-622.
294. Walker PD, Barri Y, Shah SV. Oxidant mechanisms in gentamicin nephrotoxicity. *Ren Fail* 1999; **21**: 433-442.
295. Watanabe A, Nagai J, Adachi Y, et al. Targeted prevention of renal accumulation and toxicity of gentamicin by aminoglycoside binding receptor antagonists. *J Control Release* 2004; **95**: 423-433.
296. Yanagida C, Ito K, Komiya I, et al. Protective effect of fosfomycin on gentamicin-induced lipid peroxidation of rat renal tissue. *Chem Biol Interact* 2004; **148**: 139-147.
297. Baciewicz AM, Sokos DR, Cowan RI. Aminoglycoside-associated nephrotoxicity in the elderly. *Ann Pharmacother* 2003; **37**: 182-186.
298. Barclay ML, Kirkpatrick CM, Begg EJ. Once daily aminoglycoside therapy. Is it less toxic than multiple daily doses and how should it be monitored? *Clin Pharmacokinet* 1999; **36**: 89-98.
299. Graham AC, Mercier RC, Achusim LE, et al. Extended-interval aminoglycoside dosing for treatment of enterococcal and staphylococcal osteomyelitis. *Ann Pharmacother* 2004; **38**: 936-941.
300. Kiel PJ, Lo M, Stockwell D, et al. An evaluation of amikacin nephrotoxicity in the hematology/oncology population. *Am J Ther* 2008; **15**: 131-136.
301. Kraus DM, Pai MP, Rodvold KA. Efficacy and tolerability of extended-interval aminoglycoside administration in pediatric patients. *Paediatr Drugs* 2002; **4**: 469-484.
302. Nastaas E, Bangstad HJ, Sandvik L, et al. Aminoglycoside extended interval dosing in neonates is safe and effective: a meta-analysis. *Arch Dis Child Fetal Neonatal Ed* 2005; **90**: F294-300.
303. Peloquin CA, Berning SE, Nitta AT, et al. Aminoglycoside toxicity: daily versus thrice-weekly dosing for treatment of mycobacterial diseases. *Clin Infect Dis* 2004; **38**: 1538-1544.
304. Peters-Volleberg GW, Dortant PM, Speijers GJ. Comparison of tobramycin nephrotoxicity in young adult and aged female rats. *Pharmacol Toxicol* 1999; **84**: 147-153.
305. Rougier F, Claude D, Maurin M, et al. Aminoglycoside nephrotoxicity: modeling, simulation, and control. *Antimicrob Agents Chemother* 2003; **47**: 1010-1016.
306. Rougier F, Ducher M, Maurin M, et al. Aminoglycoside dosages and nephrotoxicity: quantitative relationships. *Clin Pharmacokinet* 2003; **42**: 493-500.
307. Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. *Antimicrob Agents Chemother* 1999; **43**: 1549-1555.
308. Smyth AR, Tan KH. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. *Cochrane Database Syst Rev* 2006; **3**: CD002009.
309. Ali MZ, Goetz MB. A meta-analysis of the relative efficacy and toxicity of single daily dosing versus multiple daily dosing of aminoglycosides. *Clin Infect Dis* 1997; **24**: 796-809.
310. Bailey TC, Little JR, Littenberg B, et al. A meta-analysis of extended-interval dosing versus multiple daily dosing of aminoglycosides. *Clin Infect Dis* 1997; **24**: 786-795.
311. Barza M, Ioannidis JB, Cappelleri JC, et al. Single or multiple daily doses of aminoglycosides: a meta-analysis. *BMJ* 1996; **312**: 338-345.
312. Ferriols-Lisart R, Alos-Alminana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. *Am J Health Syst Pharm* 1996; **53**: 1141-1150.
313. Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. *Ann Intern Med* 1996; **124**: 717-725.
314. Munchhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. *J Antimicrob Chemother* 1996; **37**: 645-663.
315. Gavalda J, Onrubia PL, Gomez MT, et al. Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to *Enterococcus faecalis* with no high-level resistance to aminoglycosides. *J Antimicrob Chemother* 2003; **52**: 514-517.
316. Le T, Bayer AS. Combination antibiotic therapy for infective endocarditis. *Clin Infect Dis* 2003; **36**: 615-621.
317. Tam VH, McKinnon PS, Levine DP, et al. Once-daily aminoglycoside in the treatment of *Enterococcus faecalis* endocarditis: case report and review. *Pharmacotherapy* 2000; **20**: 1116-1119.
318. Beauchamp D, Labrecque G. Aminoglycoside nephrotoxicity: do time and frequency of administration matter? *Curr Opin Crit Care* 2001; **7**: 401-408.
319. Kim MJ, Bertino JS, Jr., Erb TA, et al. Application of Bayes theorem to aminoglycoside-associated nephrotoxicity: comparison of extended-interval dosing, individualized pharmacokinetic monitoring, and multiple-daily dosing. *J Clin Pharmacol* 2004; **44**: 696-707.
320. Murry KR, McKinnon PS, Mitrzyk B, et al. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. *Pharmacotherapy* 1999; **19**: 1252-1260.

321. Streetman DS, Nafziger AN, Destache CJ, *et al.* Individualized pharmacokinetic monitoring results in less aminoglycoside-associated nephrotoxicity and fewer associated costs. *Pharmacotherapy* 2001; **21**: 443-451.
322. Heintz BH, Matzke GR, Dager WE. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. *Pharmacotherapy* 2009; **29**: 562-577.
323. Dovas S, Liakopoulos V, Papatheodorou L, *et al.* Acute renal failure after antibiotic-impregnated bone cement treatment of an infected total knee arthroplasty. *Clin Nephrol* 2008; **69**: 207-212.
324. Boyle MP. Adult cystic fibrosis. *JAMA* 2007; **298**: 1787-1793.
325. Ramsey BW, Pepe MS, Quan JM, *et al.* Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. *N Engl J Med* 1999; **340**: 23-30.
326. Cannella CA, Wilkinson ST. Acute renal failure associated with inhaled tobramycin. *Am J Health Syst Pharm* 2006; **63**: 1858-1861.
327. Izquierdo MJ, Gomez-Alamillo C, Ortiz F, *et al.* Acute renal failure associated with use of inhaled tobramycin for treatment of chronic airway colonization with *Pseudomonas aeruginosa*. *Clin Nephrol* 2006; **66**: 464-467.
328. Harbarth S, Burke JP, Lloyd JF, *et al.* Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. *Clin Infect Dis* 2002; **35**: e120-127.
329. Ullmann AJ. Nephrotoxicity in the setting of invasive fungal diseases. *Mycoses* 2008; **51** (Suppl 1): 25-30.
330. Wingard JR, Kubilis P, Lee L, *et al.* Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. *Clin Infect Dis* 1999; **29**: 1402-1407.
331. Pai MP, Norenberg JP, Telepak RA, *et al.* Assessment of effective renal plasma flow, enzymuria, and cytokine release in healthy volunteers receiving a single dose of amphotericin B desoxycholate. *Antimicrob Agents Chemother* 2005; **49**: 3784-3788.
332. Varlam DE, Siddiq MM, Parton LA, *et al.* Apoptosis contributes to amphotericin B-induced nephrotoxicity. *Antimicrob Agents Chemother* 2001; **45**: 679-685.
333. Furrer K, Schaffner A, Vavricka SR, *et al.* Nephrotoxicity of cyclosporine A and amphotericin B-desoxycholate as continuous infusion in allogeneic stem cell transplantation. *Swiss Med Wkly* 2002; **132**: 316-320.
334. de Rosa FG, Bargiacchi O, Audagnotto S, *et al.* Continuous infusion of amphotericin B desoxycholate: does decreased nephrotoxicity couple with time-dependent pharmacodynamics? *Leuk Lymphoma* 2006; **47**: 1964-1966.
335. Sundar S, Chakravarty J, Rai VK, *et al.* Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. *Clin Infect Dis* 2007; **45**: 556-561.
336. Techapornroong M, Suankratay C. Alternate-day versus once-daily administration of amphotericin B in the treatment of cryptococcal meningitis: a randomized controlled trial. *Scand J Infect Dis* 2007; **39**: 896-901.
337. Kleinberg M. What is the current and future status of conventional amphotericin B? *Int J Antimicrob Agents* 2006; **27** (Suppl 1): 12-16.
338. Saliba F, Dupont B. Renal impairment and amphotericin B formulations in patients with invasive fungal infections. *Med Mycol* 2008; **46**: 97-112.
339. Ullmann AJ, Sanz MA, Tramarin A, *et al.* Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. *Clin Infect Dis* 2006; **43**: e29-38.
340. Yoo BK, Jalil Miah MA, Lee ES, *et al.* Reduced renal toxicity of nanoparticulate amphotericin B micelles prepared with partially benzylated poly-L-aspartic acid. *Biol Pharm Bull* 2006; **29**: 1700-1705.
341. Alexander BD, Wingard JR. Study of renal safety in amphotericin B lipid complex-treated patients. *Clin Infect Dis* 2005; **40** (Suppl 6): S414-421.
342. Cornely OA, Maertens J, Bresnik M, *et al.* Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). *Clin Infect Dis* 2007; **44**: 1289-1297.
343. Garbino J, Adam A. Use of high-dose liposomal amphotericin B: efficacy and tolerance. *Acta Biomed* 2006; **77** (Suppl 4): 19-22.
344. Girois SB, Chapuis F, Decullier E, *et al.* Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. *Eur J Clin Microbiol Infect Dis* 2005; **24**: 119-130.
345. Hachem RY, Boktour MR, Hanna HA, *et al.* Amphotericin B lipid complex versus liposomal amphotericin B monotherapy for invasive aspergillosis in patients with hematologic malignancy. *Cancer* 2008; **112**: 1282-1287.
346. Johansen HK, Gotsche PC. Amphotericin B lipid soluble formulations vs. amphotericin B in cancer patients with neutropenia. *Cochrane Database Syst Rev* 2000; **3**: CD000969.
347. Johnson PC, Wheat LJ, Cloud GA, *et al.* Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. *Ann Intern Med* 2002; **137**: 105-109.
348. Olson JA, Adler-Moore JP, Schwartz J, *et al.* Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. *Antimicrob Agents Chemother* 2006; **50**: 2122-2131.
349. Veerareddy PR, Vobalaboina V. Lipid-based formulations of amphotericin B. *Drugs Today (Barc)* 2004; **40**: 133-145.
350. Walsh TJ, Finberg RW, Arndt C, *et al.* Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. *N Engl J Med* 1999; **340**: 764-771.
351. Boogaerts M, Winston DJ, Bow EJ, *et al.* Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. *Ann Intern Med* 2001; **135**: 412-422.
352. Johansen HK, Gotsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. *Cochrane Database Syst Rev* 2002; **2**: CD000239.
353. Park SH, Choi SM, Lee DG, *et al.* Intravenous itraconazole vs. amphotericin B deoxycholate for empirical antifungal therapy in patients with persistent neutropenic fever. *Korean J Intern Med* 2006; **21**: 165-172.
354. Raad II, Hanna HA, Boktour M, *et al.* Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: posaconazole compared with high-dose lipid formulations of amphotericin B alone or in combination with caspofungin. *Leukemia* 2008; **22**: 496-503.
355. Wegner B, Baer P, Gauer S, *et al.* Caspofungin is less nephrotoxic than amphotericin B *in vitro* and predominantly damages distal renal tubular cells. *Nephrol Dial Transplant* 2005; **20**: 2071-2079.
356. Schwann NM, Horrow JC, Strong MD, 3rd, *et al.* Does off-pump coronary artery bypass reduce the incidence of clinically evident renal dysfunction after multivessel myocardial revascularization? *Anesth Analg* 2004; **99**: 959-964, table of contents.
357. Shroyer AL, Grover FL, Hattler B, *et al.* On-pump versus off-pump coronary-artery bypass surgery. *N Engl J Med* 2009; **361**: 1827-1837.
358. Seabra VF, Alobaidi S, Balk EM, *et al.* Off-pump coronary artery bypass surgery and acute kidney injury: a meta-analysis of randomized controlled trials. *Clin J Am Soc Nephrol* 2010; **5**: 1734-1744.
359. Efrati S, Dishy V, Averbukh M, *et al.* The effect of N-acetylcysteine on renal function, nitric oxide, and oxidative stress after angiography. *Kidney Int* 2003; **64**: 2182-2187.
360. Conesa EL, Valero F, Nadal JC, *et al.* N-acetyl-L-cysteine improves renal medullary hypoperfusion in acute renal failure. *Am J Physiol Regul Integr Comp Physiol* 2001; **281**: R730-737.
361. DiMari J, Megyesi J, Udvarhelyi N, *et al.* N-acetyl cysteine ameliorates ischemic renal failure. *Am J Physiol* 1997; **272**: F292-298.
362. Jiang B, Haverty M, Brecher P. N-acetyl-L-cysteine enhances interleukin-1beta-induced nitric oxide synthase expression. *Hypertension* 1999; **34**: 574-579.
363. Nitescu N, Ricksten SE, Marcussen N, *et al.* N-acetylcysteine attenuates kidney injury in rats subjected to renal ischaemia-reperfusion. *Nephrol Dial Transplant* 2006; **21**: 1240-1247.
364. Fishbane S. N-acetylcysteine in the prevention of contrast-induced nephropathy. *Clin J Am Soc Nephrol* 2008; **3**: 281-287.
365. Van Praet JT, De Vriese AS. Prevention of contrast-induced nephropathy: a critical review. *Curr Opin Nephrol Hypertens* 2007; **16**: 336-347.
366. Hoffmann U, Fischeder M, Kruger B, *et al.* The value of N-acetylcysteine in the prevention of radiocontrast agent-induced nephropathy seems questionable. *J Am Soc Nephrol* 2004; **15**: 407-410.
367. Izzedine H, Guerin V, Launay-Vacher V, *et al.* Effect of N-acetylcysteine on serum creatinine level. *Nephrol Dial Transplant* 2001; **16**: 1514-1515.
368. Haase M, Haase-Fielitz A, Ratnaik S, *et al.* N-Acetylcysteine does not artifactually lower plasma creatinine concentration. *Nephrol Dial Transplant* 2008; **23**: 1581-1587.
369. Mainra R, Gallo K, Moist L. Effect of N-acetylcysteine on renal function in patients with chronic kidney disease. *Nephrology (Carlton)* 2007; **12**: 510-513.
370. Rehman T, Fought J, Solomon R. N-acetylcysteine effect on serum creatinine and cystatin C levels in CKD patients. *Clin J Am Soc Nephrol* 2008; **3**: 1610-1614.
371. Molnar Z, Szakmany T, Koszegi T. Prophylactic N-acetylcysteine decreases serum CRP but not PCT levels and microalbuminuria following major abdominal surgery. A prospective, randomised, double-blinded, placebo-controlled clinical trial. *Intensive Care Med* 2003; **29**: 749-755.
372. Niemi TT, Munsterhjelm E, Poyhia R, *et al.* The effect of N-acetylcysteine on blood coagulation and platelet function in patients undergoing open

- repair of abdominal aortic aneurysm. *Blood Coagul Fibrinolysis* 2006; **17**: 29–34.
373. Peake SL, Moran JL, Leppard PI. N-acetyl-L-cysteine depresses cardiac performance in patients with septic shock. *Crit Care Med* 1996; **24**: 1302–1310.
374. Lynch RM, Robertson R. Anaphylactoid reactions to intravenous N-acetylcysteine: a prospective case controlled study. *Accid Emerg Nurs* 2004; **12**: 10–15.
375. Appelboom AV, Dargan PI, Knighton J. Fatal anaphylactoid reaction to N-acetylcysteine: caution in patients with asthma. *Emerg Med J* 2002; **19**: 594–595.
376. Ho KM, Morgan DJ. Meta-analysis of N-acetylcysteine to prevent acute renal failure after major surgery. *Am J Kidney Dis* 2009; **53**: 33–40.
377. Adabag AS, Ishani A, Koneswaran S, et al. Utility of N-acetylcysteine to prevent acute kidney injury after cardiac surgery: a randomized controlled trial. *Am Heart J* 2008; **155**: 1143–1149.
378. Burns KE, Chu MW, Novick RJ, et al. Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing CABG surgery: a randomized controlled trial. *JAMA* 2005; **294**: 342–350.
379. El-Hamamsy I, Stevens LM, Carrier M, et al. Effect of intravenous N-acetylcysteine on outcomes after coronary artery bypass surgery: a randomized, double-blind, placebo-controlled clinical trial. *J Thorac Cardiovasc Surg* 2007; **133**: 7–12.
380. Sisillo E, Ceriani R, Bortone F, et al. N-acetylcysteine for prevention of acute renal failure in patients with chronic renal insufficiency undergoing cardiac surgery: a prospective, randomized, clinical trial. *Crit Care Med* 2008; **36**: 81–86.
381. Wijesundera DN, Beattie WS, Rao V, et al. N-acetylcysteine for preventing acute kidney injury in cardiac surgery patients with pre-existing moderate renal insufficiency. *Can J Anaesth* 2007; **54**: 872–881.
382. Hynninen MS, Niemi TT, Poyhia R, et al. N-acetylcysteine for the prevention of kidney injury in abdominal aortic surgery: a randomized, double-blind, placebo-controlled trial. *Anesth Analg* 2006; **102**: 1638–1645.
383. Macedo E, Abdulkader R, Castro I, et al. Lack of protection of N-acetylcysteine (NAC) in acute renal failure related to elective aortic aneurysm repair—a randomized controlled trial. *Nephrol Dial Transplant* 2006; **21**: 1863–1869.
384. Komisarof JA, Gilkey GM, Peters DM, et al. N-acetylcysteine for patients with prolonged hypotension as prophylaxis for acute renal failure (NEPHRON). *Crit Care Med* 2007; **35**: 435–441.
385. Harjai KJ, Raizada A, Shenoy C, et al. A comparison of contemporary definitions of contrast nephropathy in patients undergoing percutaneous coronary intervention and a proposal for a novel nephropathy grading system. *Am J Cardiol* 2008; **101**: 812–819.
386. Thomsen HS, Morcos SK. Contrast media and the kidney: European Society of Urogenital Radiology (ESUR) guidelines. *Br J Radiol* 2003; **76**: 513–518.
387. Ribichini F, Graziani M, Gambaro G, et al. Early creatinine shifts predict contrast-induced nephropathy and persistent renal damage after angiography. *Am J Med* 2010; **123**: 755–763.
388. Newhouse JH, Kho D, Rao QA, et al. Frequency of serum creatinine changes in the absence of iodinated contrast material: implications for studies of contrast nephrotoxicity. *AJR Am J Roentgenol* 2008; **191**: 376–382.
389. Baumgarten DA, Ellis JH. Contrast-induced nephropathy: contrast material not required? *AJR Am J Roentgenol* 2008; **191**: 383–386.
390. Bruce RJ, Djamali A, Shinki K, et al. Background fluctuation of kidney function versus contrast-induced nephrotoxicity. *AJR Am J Roentgenol* 2009; **192**: 711–718.
391. Jabara R, Gadesam RR, Pendyala LK, et al. Impact of the definition utilized on the rate of contrast-induced nephropathy in percutaneous coronary intervention. *Am J Cardiol* 2009; **103**: 1657–1662.
392. Berns AS. Nephrotoxicity of contrast media. *Kidney Int* 1989; **36**: 730–740.
393. Rudnick MR, Goldfarb S, Tumlin J. Contrast-induced nephropathy: is the picture any clearer? *Clin J Am Soc Nephrol* 2008; **3**: 261–262.
394. Nash K, Hafeez A, Hou S. Hospital-acquired renal insufficiency. *Am J Kidney Dis* 2002; **39**: 930–936.
395. Polena S, Yang S, Alam R, et al. Nephropathy in critically ill patients without preexisting renal disease. *Proc West Pharmacol Soc* 2005; **48**: 134–135.
396. Becker CR, Davidson C, Lameire N, et al. High-risk situations and procedures. *Am J Cardiol* 2006; **98**: 37K–41K.
397. Lameire N. Contrast-induced nephropathy in the critically-ill patient: focus on emergency screening and prevention. *Acta Clin Belg Suppl* 2007; **346**–352.
398. McCullough PA. Radiocontrast-induced acute kidney injury. *Nephron Physiol* 2008; **109**: pp 61–72.
399. Weisbord SD, Chen H, Stone RA, et al. Associations of increases in serum creatinine with mortality and length of hospital stay after coronary angiography. *J Am Soc Nephrol* 2006; **17**: 2871–2877.
400. McCullough PA, Wolyn R, Rocher LL, et al. Acute renal failure after coronary intervention: incidence, risk factors, and relationship to mortality. *Am J Med* 1997; **103**: 368–375.
401. Solomon RJ, Natarajan MK, Doucet S, et al. Cardiac Angiography in Renally Impaired Patients (CARE) study: a randomized double-blind trial of contrast-induced nephropathy in patients with chronic kidney disease. *Circulation* 2007; **115**: 3189–3196.
402. Freeman RV, O'Donnell M, Share D, et al. Nephropathy requiring dialysis after percutaneous coronary intervention and the critical role of an adjusted contrast dose. *Am J Cardiol* 2002; **90**: 1068–1073.
403. Nikolsky E, Mehran R, Turcot D, et al. Impact of chronic kidney disease on prognosis of patients with diabetes mellitus treated with percutaneous coronary intervention. *Am J Cardiol* 2004; **94**: 300–305.
404. Vuurmans T, Byrne J, Fretz E, et al. Chronic kidney injury in patients after cardiac catheterisation or percutaneous coronary intervention: a comparison of radial and femoral approaches (from the British Columbia Cardiac and Renal Registries). *Heart* 2010; **96**: 1538–1542.
405. Drey N, Roderick P, Mullee M, et al. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. *Am J Kidney Dis* 2003; **42**: 677–684.
406. Katzberg RW, Haller C. Contrast-induced nephrotoxicity: clinical landscape. *Kidney Int Suppl* 2006; **53**–7.
407. Persson PB. Editorial: contrast medium-induced nephropathy. *Nephrol Dial Transplant* 2005; **20** (Suppl 1): i1.
408. Mehran R, Nikolsky E. Contrast-induced nephropathy: definition, epidemiology, and patients at risk. *Kidney Int Suppl* 2006; **511**–15.
409. Stevens LA, Coresh J, Greene T, et al. Assessing kidney function—measured and estimated glomerular filtration rate. *N Engl J Med* 2006; **354**: 2473–2483.
410. Lameire N, Adam A, Becker CR, et al. Baseline renal function screening. *Am J Cardiol* 2006; **98**: 21K–26K.
411. Choyke PL, Cady J, DePollar SL, et al. Determination of serum creatinine prior to iodinated contrast media: is it necessary in all patients? *Tech Urol* 1998; **4**: 65–69.
412. McCullough PA, Adam A, Becker CR, et al. Risk prediction of contrast-induced nephropathy. *Am J Cardiol* 2006; **98**: 27K–36K.
413. Toprak O. Conflicting and new risk factors for contrast induced nephropathy. *J Urol* 2007; **178**: 2277–2283.
414. Goldenberg I, Matetzky S. Nephropathy induced by contrast media: pathogenesis, risk factors and preventive strategies. *CMAJ* 2005; **172**: 1461–1471.
415. Majumdar SR, Kjellstrand CM, Tymchak WJ, et al. Forced euvolemic diuresis with mannitol and furosemide for prevention of contrast-induced nephropathy in patients with CKD undergoing coronary angiography: a randomized controlled trial. *Am J Kidney Dis* 2009; **54**: 602–609.
416. Barrett BJ, Parfrey PS. Clinical practice. Preventing nephropathy induced by contrast medium. *N Engl J Med* 2006; **354**: 379–386.
417. Brown JR, DeVries JT, Piper WD, et al. Serious renal dysfunction after percutaneous coronary interventions can be predicted. *Am Heart J* 2008; **155**: 260–266.
418. Mehran R, Aymong ED, Nikolsky E, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: development and initial validation. *J Am Coll Cardiol* 2004; **44**: 1393–1399.
419. Perazella MA. Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis. *Curr Drug Saf* 2008; **3**: 67–75.
420. Perazella MA. Current status of gadolinium toxicity in patients with kidney disease. *Clin J Am Soc Nephrol* 2009; **4**: 461–469.
421. Briguori C, Colombo A, Airolidi F, et al. Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. *Catheter Cardiovasc Interv* 2006; **67**: 175–180.
422. Ergun I, Keven K, Uruc I, et al. The safety of gadolinium in patients with stage 3 and 4 renal failure. *Nephrol Dial Transplant* 2006; **21**: 697–700.
423. Erley CM, Bader BD, Berger ED, et al. Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotaemic patients. *Nephrol Dial Transplant* 2004; **19**: 2526–2531.
424. Kane GC, Stanson AW, Kalnicka D, et al. Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes. *Nephrol Dial Transplant* 2008; **23**: 1233–1240.
425. Sam AD, 2nd, Morasch MD, Collins J, et al. Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. *J Vasc Surg* 2003; **38**: 313–318.

426. Swan SK, Lambrecht LJ, Townsend R, *et al.* Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. *Invest Radiol* 1999; **34**: 443–448.
427. Kanal E, Broome DR, Martin DR, *et al.* Response to the FDA's May 23, 2007, nephrogenic systemic fibrosis update. *Radiology* 2008; **246**: 11–14.
428. Kay J. Nephrogenic systemic fibrosis: a gadolinium-associated fibrosing disorder in patients with renal dysfunction. *Ann Rheum Dis* 2008; **67** (Suppl 3): iii66–69.
429. Wollanka H, Weidenmaier W, Giersig C. NSF after Gadovist exposure: a case report and hypothesis of NSF development. *Nephrol Dial Transplant* 2009; **24**: 3882–3884.
430. Elmholt TR, Jørgensen B, Ramsing M, *et al.* Two cases of nephrogenic systemic fibrosis after exposure to the macrocyclic compound gadobutrol. *NDT Plus* 2010; **3**: 285–287.
431. Sterling KA, Tehrani T, Rudnick MR. Clinical significance and preventive strategies for contrast-induced nephropathy. *Curr Opin Nephrol Hypertens* 2008; **17**: 616–623.
432. Kelly AM, Dwamena B, Cronin P, *et al.* Meta-analysis: effectiveness of drugs for preventing contrast-induced nephropathy. *Ann Intern Med* 2008; **148**: 284–294.
433. Cigarroa RG, Lange RA, Williams RH, *et al.* Dosing of contrast material to prevent contrast nephropathy in patients with renal disease. *Am J Med* 1989; **86**: 649–652.
434. Chen ML, Lesko L, Williams RL. Measures of exposure versus measures of rate and extent of absorption. *Clin Pharmacokinet* 2001; **40**: 565–572.
435. Sherwin PF, Cambron R, Johnson JA, *et al.* Contrast dose-to-creatinine clearance ratio as a potential indicator of risk for radiocontrast-induced nephropathy: correlation of D/CrCL with area under the contrast concentration-time curve using iodixanol. *Invest Radiol* 2005; **40**: 598–603.
436. Nyman U, Bjork J, Aspelin P, *et al.* Contrast medium dose-to-GFR ratio: a measure of systemic exposure to predict contrast-induced nephropathy after percutaneous coronary intervention. *Acta Radiol* 2008; **49**: 658–667.
437. Laskey WK, Jenkins C, Selzer F, *et al.* Volume-to-creatinine clearance ratio: a pharmacokinetically based risk factor for prediction of early creatinine increase after percutaneous coronary intervention. *J Am Coll Cardiol* 2007; **50**: 584–590.
438. Nyman U, Almen T, Aspelin P, *et al.* Contrast-medium-induced nephropathy correlated to the ratio between dose in gram iodine and estimated GFR in ml/min. *Acta Radiol* 2005; **46**: 830–842.
439. Marenzi G, Assanelli E, Campodonico J, *et al.* Contrast volume during primary percutaneous coronary intervention and subsequent contrast-induced nephropathy and mortality. *Ann Intern Med* 2009; **150**: 170–177.
440. Cramer BC, Parfrey PS, Hutchinson TA, *et al.* Renal function following infusion of radiologic contrast material. A prospective controlled study. *Arch Intern Med* 1985; **145**: 87–89.
441. Heller CA, Knapp J, Halliday J, *et al.* Failure to demonstrate contrast nephrotoxicity. *Med J Aust* 1991; **155**: 329–332.
442. Rao QA, Newhouse JH. Risk of nephropathy after intravenous administration of contrast material: a critical literature analysis. *Radiology* 2006; **239**: 392–397.
443. Barrett BJ, Katzberg RW, Thomsen HS, *et al.* Contrast-induced nephropathy in patients with chronic kidney disease undergoing computed tomography: a double-blind comparison of iodixanol and iopamidol. *Invest Radiol* 2006; **41**: 815–821.
444. Katzberg RW, Lamba R. Contrast-induced nephropathy after intravenous administration: fact or fiction? *Radiol Clin North Am* 2009; **47**: 789–800.
445. Katzberg RW, Barrett BJ. Risk of iodinated contrast material-induced nephropathy with intravenous administration. *Radiology* 2007; **243**: 622–628.
446. Thomsen HS, Morcos SK. Risk of contrast-medium-induced nephropathy in high-risk patients undergoing MDCT—a pooled analysis of two randomized trials. *Eur Radiol* 2009; **19**: 891–897.
447. Ellis JH, Cohan RH. Reducing the risk of contrast-induced nephropathy: a perspective on the controversies. *AJR Am J Roentgenol* 2009; **192**: 1544–1549.
448. Goldfarb S, Spinler S, Berns JS, *et al.* Low-osmolality contrast media and the risk of contrast-associated nephrotoxicity. *Invest Radiol* 1993; **28** (Suppl 5): S7–10; discussion S11–12.
449. Barrett BJ, Carlisle EJ. Metaanalysis of the relative nephrotoxicity of high- and low-osmolality iodinated contrast media. *Radiology* 1993; **188**: 171–178.
450. Aspelin P, Aubry P, Fransson SG, *et al.* Nephrotoxic effects in high-risk patients undergoing angiography. *N Engl J Med* 2003; **348**: 491–499.
451. Feldkamp T, Baumgart D, Elsner M, *et al.* Nephrotoxicity of iso-osmolar versus low-osmolar contrast media is equal in low risk patients. *Clin Nephrol* 2006; **66**: 322–330.
452. Hardiek KJ, Katholi RE, Robbs RS, *et al.* Renal effects of contrast media in diabetic patients undergoing diagnostic or interventional coronary angiography. *J Diabetes Complications* 2008; **22**: 171–177.
453. Juergens CP, Winter JP, Nguyen-Do P, *et al.* Nephrotoxic effects of iodixanol and iopromide in patients with abnormal renal function receiving N-acetylcysteine and hydration before coronary angiography and intervention: a randomized trial. *Intern Med J* 2009; **39**: 25–31.
454. Laskey W, Aspelin P, Davidson C, *et al.* Nephrotoxicity of iodixanol versus iopamidol in patients with chronic kidney disease and diabetes mellitus undergoing coronary angiographic procedures. *Am Heart J* 2009; **158**: 822–828 e823.
455. Nie B, Cheng WJ, Li YF, *et al.* A prospective, double-blind, randomized, controlled trial on the efficacy and cardiorenal safety of iodixanol vs. iopromide in patients with chronic kidney disease undergoing coronary angiography with or without percutaneous coronary intervention. *Catheter Cardiovasc Interv* 2008; **72**: 958–965.
456. Rudnick MR, Davidson C, Laskey W, *et al.* Nephrotoxicity of iodixanol versus ioversol in patients with chronic kidney disease: the Visipaque Angiography/Interventions with Laboratory Outcomes in Renal Insufficiency (VALOR) Trial. *Am Heart J* 2008; **156**: 776–782.
457. Heinrich MC, Haberle L, Muller V, *et al.* Nephrotoxicity of iso-osmolar iodixanol compared with nonionic low-osmolar contrast media: meta-analysis of randomized controlled trials. *Radiology* 2009; **250**: 68–86.
458. Reddan D, Laville M, Garovic VD. Contrast-induced nephropathy and its prevention: What do we really know from evidence-based findings? *J Nephrol* 2009; **22**: 333–351.
459. Jo SH, Youn TJ, Koo BK, *et al.* Renal toxicity evaluation and comparison between visipaque (iodixanol) and hexabrix (ioxaglate) in patients with renal insufficiency undergoing coronary angiography: the RECOVER study: a randomized controlled trial. *J Am Coll Cardiol* 2006; **48**: 924–930.
460. Mehran R, Nikolsky E, Kirtane AJ, *et al.* Ionic low-osmolar versus nonionic iso-osmolar contrast media to obviate worsening nephropathy after angioplasty in chronic renal failure patients: the ICON (Ionic versus nonionic Contrast to Obviate worsening Nephropathy after angioplasty in chronic renal failure patients) study. *JACC Cardiovasc Interv* 2009; **2**: 415–421.
461. Kuhn MJ, Chen N, Sahani DV, *et al.* The PREDICT study: a randomized double-blind comparison of contrast-induced nephropathy after low- or isoosmolar contrast agent exposure. *AJR Am J Roentgenol* 2008; **191**: 151–157.
462. Thomsen HS, Morcos SK, Erley CM, *et al.* The ACTIVE Trial: comparison of the effects on renal function of iomeprol-400 and iodixanol-320 in patients with chronic kidney disease undergoing abdominal computed tomography. *Invest Radiol* 2008; **43**: 170–178.
463. Nguyen SA, Suranyi P, Ravenel JG, *et al.* Iso-osmolality versus low-osmolality iodinated contrast medium at intravenous contrast-enhanced CT: effect on kidney function. *Radiology* 2008; **248**: 97–105.
464. Weisbord SD, Palevsky PM. Prevention of contrast-induced nephropathy with volume expansion. *Clin J Am Soc Nephrol* 2008; **3**: 273–280.
465. Persson PB, Hansell P, Liss P. Pathophysiology of contrast medium-induced nephropathy. *Kidney Int* 2005; **68**: 14–22.
466. Better OS, Rubinstein I. Management of shock and acute renal failure in casualties suffering from the crush syndrome. *Ren Fail* 1997; **19**: 647–653.
467. Weisbord SD, Mor MK, Resnick AL, *et al.* Prevention, incidence, and outcomes of contrast-induced acute kidney injury. *Arch Intern Med* 2008; **168**: 1325–1332.
468. Stevens MA, McCullough PA, Tobin KJ, *et al.* A prospective randomized trial of prevention measures in patients at high risk for contrast nephropathy: results of the P.R.I.N.C.E. Study. Prevention of Radiocontrast Induced Nephropathy Clinical Evaluation. *J Am Coll Cardiol* 1999; **33**: 403–411.
469. Mueller C, Buerkle G, Buettner HJ, *et al.* Prevention of contrast media-associated nephropathy: randomized comparison of 2 hydration regimens in 1620 patients undergoing coronary angioplasty. *Arch Intern Med* 2002; **162**: 329–336.
470. Merten GJ, Burgess WP, Gray LV, *et al.* Prevention of contrast-induced nephropathy with sodium bicarbonate: a randomized controlled trial. *JAMA* 2004; **291**: 2328–2334.
471. Caulfield JL, Singh SP, Wishnok JS, *et al.* Bicarbonate inhibits N-nitrosation in oxygenated nitric oxide solutions. *J Biol Chem* 1996; **271**: 25859–25863.
472. Bakris GL, Lass N, Gaber AO, *et al.* Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. *Am J Physiol* 1990; **258**: F115–120.
473. Halliwell B, Gutteridge JM. Role of free radicals and catalytic metal ions in human disease: an overview. *Methods Enzymol* 1990; **186**: 1–85.
474. Assadi F. Acetazolamide for prevention of contrast-induced nephropathy: a new use for an old drug. *Pediatr Cardiol* 2006; **27**: 238–242.

475. Brar SS, Hiremath S, Dangas G, *et al.* Sodium bicarbonate for the prevention of contrast induced-acute kidney injury: a systematic review and meta-analysis. *Clin J Am Soc Nephrol* 2009; **4**: 1584–1592.
476. Hogan SE, L'Allier P, Chetcuti S, *et al.* Current role of sodium bicarbonate-based preprocedural hydration for the prevention of contrast-induced acute kidney injury: a meta-analysis. *Am Heart J* 2008; **156**: 414–421.
477. Hoste EA, De Waele JJ, Gevaert SA, *et al.* Sodium bicarbonate for prevention of contrast-induced acute kidney injury: a systematic review and meta-analysis. *Nephrol Dial Transplant* 2010; **25**: 747–758.
478. Joannidis M, Schmid M, Wiedermann CJ. Prevention of contrast media-induced nephropathy by isotonic sodium bicarbonate: a meta-analysis. *Wien Klin Wochenschr* 2008; **120**: 742–748.
479. Kanbay M, Covic A, Coca SG, *et al.* Sodium bicarbonate for the prevention of contrast-induced nephropathy: a meta-analysis of 17 randomized trials. *Int Urol Nephrol* 2009; **41**: 617–627.
480. Navaneethan SD, Singh S, Appasamy S, *et al.* Sodium bicarbonate therapy for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. *Am J Kidney Dis* 2009; **53**: 617–627.
481. Zoungas S, Ninomiya T, Huxley R, *et al.* Systematic review: sodium bicarbonate treatment regimens for the prevention of contrast-induced nephropathy. *Ann Intern Med* 2009; **151**: 631–638.
482. Adolph E, Holdt-Lehmann B, Chatterjee T, *et al.* Renal Insufficiency Following Radioccontrast Exposure Trial (REINFORCE): a randomized comparison of sodium bicarbonate versus sodium chloride hydration for the prevention of contrast-induced nephropathy. *Coron Artery Dis* 2008; **19**: 413–419.
483. Ozcan EE, Guneri S, Akdeniz B, *et al.* Sodium bicarbonate, N-acetylcysteine, and saline for prevention of radioccontrast-induced nephropathy. A comparison of 3 regimens for protecting contrast-induced nephropathy in patients undergoing coronary procedures. A single-center prospective controlled trial. *Am Heart J* 2007; **154**: 539–544.
484. Brar SS, Shen AY, Jorgensen MB, *et al.* Sodium bicarbonate vs sodium chloride for the prevention of contrast medium-induced nephropathy in patients undergoing coronary angiography: a randomized trial. *JAMA* 2008; **300**: 1038–1046.
485. Budhiraja P, Chen Z, Popovtzer M. Sodium bicarbonate versus normal saline for protection against contrast nephropathy. *Ren Fail* 2009; **31**: 118–123.
486. Briguori C, Airoidi F, D'Andrea D, *et al.* Renal Insufficiency Following Contrast Media Administration Trial (REMEDIAL): a randomized comparison of 3 preventive strategies. *Circulation* 2007; **115**: 1211–1217.
487. Maioli M, Toso A, Leoncini M, *et al.* Sodium bicarbonate versus saline for the prevention of contrast-induced nephropathy in patients with renal dysfunction undergoing coronary angiography or intervention. *J Am Coll Cardiol* 2008; **52**: 599–604.
488. Recio-Mayoral A, Chaparro M, Prado B, *et al.* The reno-protective effect of hydration with sodium bicarbonate plus N-acetylcysteine in patients undergoing emergency percutaneous coronary intervention: the RENO Study. *J Am Coll Cardiol* 2007; **49**: 1283–1288.
489. From AM, Bartholmai BJ, Williams AW, *et al.* Sodium bicarbonate is associated with an increased incidence of contrast nephropathy: a retrospective cohort study of 7977 patients at mayo clinic. *Clin J Am Soc Nephrol* 2008; **3**: 10–18.
490. Taylor AJ, Hotchkiss D, Morse RW, *et al.* PREPARED: Preparation for Angiography in Renal Dysfunction: a randomized trial of inpatient vs outpatient hydration protocols for cardiac catheterization in mild-to-moderate renal dysfunction. *Chest* 1998; **114**: 1570–1574.
491. Trivedi HS, Moore H, Nasr S, *et al.* A randomized prospective trial to assess the role of saline hydration on the development of contrast nephrotoxicity. *Nephron Clin Pract* 2003; **93**: C29–34.
492. Yoshikawa D, Isobe S, Sato K, *et al.* Importance of oral fluid intake after coronary computed tomography angiography: An observational study. *Eur J Radiol* 2011; **77**: 118–122.
493. Cho R, Javed N, Traub D, *et al.* Oral hydration and alkalization is noninferior to intravenous therapy for prevention of contrast-induced nephropathy in patients with chronic kidney disease. *J Interv Cardiol* 2010; **23**: 460–466.
494. McCullough PA. Contrast-induced acute kidney injury. *J Am Coll Cardiol* 2008; **51**: 1419–1428.
495. Klein-Schwartz W, Doyon S. Intravenous acetylcysteine for the treatment of acetaminophen overdose. *Expert Opin Pharmacother* 2011; **12**: 119–130.
496. Thiele H, Hildebrand L, Schirdewahn C, *et al.* Impact of high-dose N-acetylcysteine versus placebo on contrast-induced nephropathy and myocardial reperfusion injury in unselected patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. The LIPSIA-N-ACC (Prospective, Single-Blind, Placebo-Controlled, Randomized Leipzig Immediate Percutaneous Coronary Intervention Acute Myocardial Infarction N-ACC) Trial. *J Am Coll Cardiol* 2010; **55**: 2201–2209.
497. Trivedi H, Daram S, Szabo A, *et al.* High-dose N-acetylcysteine for the prevention of contrast-induced nephropathy. *Am J Med* 2009; **122**: 874.e9–874.15.
498. Marenzi G, Assanelli E, Marana I, *et al.* N-acetylcysteine and contrast-induced nephropathy in primary angioplasty. *N Engl J Med* 2006; **354**: 2773–2782.
499. Webb JG, Pate GE, Humphries KH, *et al.* A randomized controlled trial of intravenous N-acetylcysteine for the prevention of contrast-induced nephropathy after cardiac catheterization: lack of effect. *Am Heart J* 2004; **148**: 422–429.
500. Bagshaw SM, McAlister FA, Manns BJ, *et al.* Acetylcysteine in the prevention of contrast-induced nephropathy: a case study of the pitfalls in the evolution of evidence. *Arch Intern Med* 2006; **166**: 161–166.
501. Vaitkus PT, Brar C. N-acetylcysteine in the prevention of contrast-induced nephropathy: publication bias perpetuated by meta-analyses. *Am Heart J* 2007; **153**: 275–280.
502. Jo SH, Koo BK, Park JS, *et al.* N-acetylcysteine versus Ascorbic acid for preventing contrast-Induced nephropathy in patients with renal insufficiency undergoing coronary angiography NASPI study-a prospective randomized controlled trial. *Am Heart J* 2009; **157**: 576–583.
503. Brown JR, Block CA, Malenka DJ, *et al.* Sodium bicarbonate plus N-acetylcysteine prophylaxis: a meta-analysis. *JACC Cardiovasc Interv* 2009; **2**: 1116–1124.
504. Koc F, Ozdemir K, Kaya MG, *et al.* Intravenous N-acetylcysteine plus high-dose hydration versus high-dose hydration and standard hydration for the prevention of contrast-induced nephropathy: CASIS-A multicenter prospective controlled trial. *Int J Cardiol* 2010; doi:10.1016/j.ijcard.2010.10.1010.1041.
505. Arend LJ, Bakris GL, Burnett JC, Jr., *et al.* Role for intrarenal adenosine in the renal hemodynamic response to contrast media. *J Lab Clin Med* 1987; **110**: 406–411.
506. Bagshaw SM, Ghali WA. Theophylline for prevention of contrast-induced nephropathy: a systematic review and meta-analysis. *Arch Intern Med* 2005; **165**: 1087–1093.
507. Huber W, Eckel F, Hennig M, *et al.* Prophylaxis of contrast material-induced nephropathy in patients in intensive care: acetylcysteine, theophylline, or both? A randomized study. *Radiology* 2006; **239**: 793–804.
508. Baskurt M, Okcun B, Abaci O, *et al.* N-acetylcysteine versus N-acetylcysteine + theophylline for the prevention of contrast nephropathy. *Eur J Clin Invest* 2009; **39**: 793–799.
509. Malhis M, Al-Bitar S, Al-Deen Zaiat K. The role of theophylline in prevention of radioccontrast media-induced nephropathy. *Saudi J Kidney Dis Transpl* 2010; **21**: 276–283.
510. Upton RA. Pharmacokinetic interactions between theophylline and other medication (Part II). *Clin Pharmacokinet* 1991; **20**: 135–150.
511. Upton RA. Pharmacokinetic interactions between theophylline and other medication (Part I). *Clin Pharmacokinet* 1991; **20**: 66–80.
512. Stacul F, Adam A, Becker CR, *et al.* Strategies to reduce the risk of contrast-induced nephropathy. *Am J Cardiol* 2006; **98**: 59K–77K.
513. Allaqband S, Tumuluri R, Malik AM, *et al.* Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radioccontrast-induced nephropathy. *Catheter Cardiovasc Interv* 2002; **57**: 279–283.
514. Toso A, Maioli M, Leoncini M, *et al.* Usefulness of atorvastatin (80 mg) in prevention of contrast-induced nephropathy in patients with chronic renal disease. *Am J Cardiol* 2010; **105**: 288–292.
515. Yoshida S, Kamihata H, Nakamura S, *et al.* Prevention of contrast-induced nephropathy by chronic pravastatin treatment in patients with cardiovascular disease and renal insufficiency. *J Cardiol* 2009; **54**: 192–198.
516. Deray G. Dialysis and iodinated contrast media. *Kidney Int Suppl* 2006; **S25–29**.
517. Cruz DN, Perazella MA, Ronco C. The role of extracorporeal blood purification therapies in the prevention of radioccontrast-induced nephropathy. *Int J Artif Organs* 2008; **31**: 515–524.
518. Vogt B, Ferrari P, Schonholzer C, *et al.* Prophylactic hemodialysis after radioccontrast media in patients with renal insufficiency is potentially harmful. *Am J Med* 2001; **111**: 692–698.
519. Reinecke H, Fobker M, Wellmann J, *et al.* A randomized controlled trial comparing hydration therapy to additional hemodialysis or N-acetylcysteine for the prevention of contrast medium-induced nephropathy: the Dialysis-versus-Diuresis (DVD) Trial. *Clin Res Cardiol* 2007; **96**: 130–139.
520. Kawashima S, Takano H, Iino Y, *et al.* Prophylactic hemodialysis does not prevent contrast-induced nephropathy after cardiac catheterization in patients with chronic renal insufficiency. *Circ J* 2006; **70**: 553–558.

521. Lee PT, Chou KJ, Liu CP, *et al*. Renal protection for coronary angiography in advanced renal failure patients by prophylactic hemodialysis. A randomized controlled trial. *J Am Coll Cardiol* 2007; **50**: 1015–1020.
522. Marenzi G, Marana I, Lauri G, *et al*. The prevention of radiocontrast-agent-induced nephropathy by hemofiltration. *N Engl J Med* 2003; **349**: 1333–1340.
523. Marenzi G, Lauri G, Campodonico J, *et al*. Comparison of two hemofiltration protocols for prevention of contrast-induced nephropathy in high-risk patients. *Am J Med* 2006; **119**: 155–162.
524. Kellum JA, Mehta RL, Levin A, *et al*. Development of a clinical research agenda for acute kidney injury using an international, interdisciplinary, three-step modified Delphi process. *Clin J Am Soc Nephrol* 2008; **3**: 887–894.
525. Palevsky PM, Baldwin I, Davenport A, *et al*. Renal replacement therapy and the kidney: minimizing the impact of renal replacement therapy on recovery of acute renal failure. *Curr Opin Crit Care* 2005; **11**: 548–554.
526. Allon M, Shanklin N. Effect of albuterol treatment on subsequent dialytic potassium removal. *Am J Kidney Dis* 1995; **26**: 607–613.
527. Gauthier PM, Szerlip HM. Metabolic acidosis in the intensive care unit. *Crit Care Clin* 2002; **18**: 289–308.
528. Kraut JA, Kurtz I. Toxic alcohol ingestions: clinical features, diagnosis, and management. *Clin J Am Soc Nephrol* 2008; **3**: 208–225.
529. Pearlman BL, Gambhir R. Salicylate intoxication: a clinical review. *Postgrad Med* 2009; **121**: 162–168.
530. Tyagi PK, Winchester JF, Feinfeld DA. Extracorporeal removal of toxins. *Kidney Int* 2008; **74**: 1231–1233.
531. Bouman CS, Oudemans-Van Straaten HM, Tijssen JG, *et al*. Effects of early high-volume continuous venovenous hemofiltration on survival and recovery of renal function in intensive care patients with acute renal failure: a prospective, randomized trial. *Crit Care Med* 2002; **30**: 2205–2211.
532. Conger JD. A controlled evaluation of prophylactic dialysis in post-traumatic acute renal failure. *J Trauma* 1975; **15**: 1056–1063.
533. Fischer RP, Griffen WO, Jr., Reiser M, *et al*. Early dialysis in the treatment of acute renal failure. *Surg Gynecol Obstet* 1966; **123**: 1019–1023.
534. Kleinknecht D, Jungers P, Chanard J, *et al*. Uremic and non-uremic complications in acute renal failure: Evaluation of early and frequent dialysis on prognosis. *Kidney Int* 1972; **1**: 190–196.
535. Parsons FM, Hobson SM, Blagg CR, *et al*. Optimum time for dialysis in acute reversible renal failure. Description and value of an improved dialyser with large surface area. *Lancet* 1961; **1**: 129–134.
536. Gettings LG, Reynolds HN, Scalea T. Outcome in post-traumatic acute renal failure when continuous renal replacement therapy is applied early vs. late. *Intensive Care Med* 1999; **25**: 805–813.
537. Demirkilic U, Kuralay E, Yenicesu M, *et al*. Timing of replacement therapy for acute renal failure after cardiac surgery. *J Card Surg* 2004; **19**: 17–20.
538. Elahi MM, Lim MY, Joseph RN, *et al*. Early hemofiltration improves survival in post-cardiotomy patients with acute renal failure. *Eur J Cardiothorac Surg* 2004; **26**: 1027–1031.
539. Liu KD, Himmelfarb J, Paganini E, *et al*. Timing of initiation of dialysis in critically ill patients with acute kidney injury. *Clin J Am Soc Nephrol* 2006; **1**: 915–919.
540. Bagshaw SM, Uchino S, Bellomo R, *et al*. Timing of renal replacement therapy and clinical outcomes in critically ill patients with severe acute kidney injury. *J Crit Care* 2009; **24**: 129–140.
541. Shiao CC, Wu VC, Li WY, *et al*. Late initiation of renal replacement therapy is associated with worse outcomes in acute kidney injury after major abdominal surgery. *Crit Care* 2009; **13**: R171.
542. Brandstrup B, Tonnesen H, Beier-Holgersen R, *et al*. Effects of intravenous fluid restriction on postoperative complications: comparison of two perioperative fluid regimens: a randomized assessor-blinded multicenter trial. *Ann Surg* 2003; **238**: 641–648.
543. Folland JA, Fortenberry JD, Warshaw BL, *et al*. Fluid overload before continuous hemofiltration and survival in critically ill children: a retrospective analysis. *Crit Care Med* 2004; **32**: 1771–1776.
544. Gillespie RS, Seidel K, Symons JM. Effect of fluid overload and dose of replacement fluid on survival in hemofiltration. *Pediatr Nephrol* 2004; **19**: 1394–1399.
545. Goldstein SL, Currier H, Graf C, *et al*. Outcome in children receiving continuous venovenous hemofiltration. *Pediatrics* 2001; **107**: 1309–1312.
546. Goldstein SL, Somers MJ, Baum MA, *et al*. Pediatric patients with multi-organ dysfunction syndrome receiving continuous renal replacement therapy. *Kidney Int* 2005; **67**: 653–658.
547. Hayes LW, Oster RA, Tofil NM, *et al*. Outcomes of critically ill children requiring continuous renal replacement therapy. *J Crit Care* 2009; **24**: 394–400.
548. Sutherland SM, Zappitelli M, Alexander SR, *et al*. Fluid overload and mortality in children receiving continuous renal replacement therapy: the prospective pediatric continuous renal replacement therapy registry. *Am J Kidney Dis* 2010; **55**: 316–325.
549. Wiedemann HP, Wheeler AP, Bernard GR, *et al*. Comparison of two fluid-management strategies in acute lung injury. *N Engl J Med* 2006; **354**: 2564–2575.
550. Mehta RL, McDonald B, Pahl M, *et al*. Continuous vs. intermittent dialysis for acute renal failure in the ICU: Results from a randomized multicenter trial (abstract). *J Am Soc Nephrol* 1996; **7**: 1456.
551. Cruz DN, de Cal M, Garzotto F, *et al*. Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population. *Intensive Care Med* 2010; **36**: 444–451.
552. Hui-Stickle S, Brewer ED, Goldstein SL. Pediatric ARF epidemiology at a tertiary care center from 1999 to 2001. *Am J Kidney Dis* 2005; **45**: 96–101.
553. Williams DM, Sreedhar SS, Mickell JJ, *et al*. Acute kidney failure: a pediatric experience over 20 years. *Arch Pediatr Adolesc Med* 2002; **156**: 893–900.
554. Picca S, Dionisi-Vici C, Abeni D, *et al*. Extracorporeal dialysis in neonatal hyperammonemia: modalities and prognostic indicators. *Pediatr Nephrol* 2001; **16**: 862–867.
555. Proulx F, Fayon M, Farrell CA, *et al*. Epidemiology of sepsis and multiple organ dysfunction syndrome in children. *Chest* 1996; **109**: 1033–1037.
556. Proulx F, Gauthier M, Nadeau D, *et al*. Timing and predictors of death in pediatric patients with multiple organ system failure. *Crit Care Med* 1994; **22**: 1025–1031.
557. Picca S, Bartuli A, Dionisi-Vici C. Medical management and dialysis therapy for the infant with an inborn error of metabolism. *Semin Nephrol* 2008; **28**: 477–480.
558. Picca S, Ricci Z, Picardo S. Acute kidney injury in an infant after cardiopulmonary bypass. *Semin Nephrol* 2008; **28**: 470–476.
559. Michael M, Kuehnle I, Goldstein SL. Fluid overload and acute renal failure in pediatric stem cell transplant patients. *Pediatr Nephrol* 2004; **19**: 91–95.
560. Goldstein SL. Advances in pediatric renal replacement therapy for acute kidney injury. *Semin Dial* 2011; **24**: 187–191.
561. Bagshaw SM, Mortis G, Godinez-Luna T, *et al*. Renal recovery after severe acute renal failure. *Int J Artif Organs* 2006; **29**: 1023–1030.
562. Bellomo R, Cass A, Cole L, *et al*. Intensity of continuous renal-replacement therapy in critically ill patients. *N Engl J Med* 2009; **361**: 1627–1638.
563. Palevsky PM, Zhang JH, O'Connor TZ, *et al*. Intensity of renal support in critically ill patients with acute kidney injury. *N Engl J Med* 2008; **359**: 7–20.
564. Prendergast TJ, Luce JM. Increasing incidence of withholding and withdrawal of life support from the critically ill. *Am J Respir Crit Care Med* 1997; **155**: 15–20.
565. Swartz R, Perry E, Daley J. The frequency of withdrawal from acute care is impacted by severe acute renal failure. *J Palliat Med* 2004; **7**: 676–682.
566. Ho KM, Liang J, Hughes T, *et al*. Withholding and withdrawal of therapy in patients with acute renal injury: a retrospective cohort study. *Anaesth Intensive Care* 2003; **31**: 509–513.
567. Shealy CB, Campbell RC, Hey JC, *et al*. 24-hr creatinine clearance as a guide for CRRT withdrawal: a retrospective study (abstr). *Blood Purif* 2003; **21**: 192.
568. Wu VC, Ko WJ, Chang HW, *et al*. Risk factors of early redialysis after weaning from postoperative acute renal replacement therapy. *Intensive Care Med* 2008; **34**: 101–108.
569. Askenazi DJ, Feig DI, Graham NM, *et al*. 3–5 year longitudinal follow-up of pediatric patients after acute renal failure. *Kidney Int* 2006; **69**: 184–189.
570. Symons JM, Chua AN, Somers MJ, *et al*. Demographic characteristics of pediatric continuous renal replacement therapy: a report of the prospective pediatric continuous renal replacement therapy registry. *Clin J Am Soc Nephrol* 2007; **2**: 732–738.
571. Schetz M. Anticoagulation in continuous renal replacement therapy. *Contrib Nephrol* 2001; **132**: 283–303.
572. Bellomo R, Parkin G, Love J, *et al*. Use of continuous haemodiafiltration: an approach to the management of acute renal failure in the critically ill. *Am J Nephrol* 1992; **12**: 240–245.
573. Morabito S, Guzzo I, Solazzo A, *et al*. Continuous renal replacement therapies: anticoagulation in the critically ill at high risk of bleeding. *J Nephrol* 2003; **16**: 566–571.
574. Tan HK, Baldwin I, Bellomo R. Continuous veno-venous hemofiltration without anticoagulation in high-risk patients. *Intensive Care Med* 2000; **26**: 1652–1657.
575. Uchino S, Fealy N, Baldwin I, *et al*. Continuous venovenous hemofiltration without anticoagulation. *ASAIO J* 2004; **50**: 76–80.
576. Agarwal B, Shaw S, Hari MS, *et al*. Continuous renal replacement therapy (CRRT) in patients with liver disease: is circuit life different? *J Hepatol* 2009; **51**: 504–509.
577. Davies H, Leslie G. Maintaining the CRRT circuit: non-anticoagulant alternatives. *Aust Crit Care* 2006; **19**: 133–138.

578. Joannidis M, Oudemans-van Straaten HM. Clinical review: Patency of the circuit in continuous renal replacement therapy. *Crit Care* 2007; **11**: 218.
579. Davenport A. Review article: Low-molecular-weight heparin as an alternative anticoagulant to unfractionated heparin for routine outpatient haemodialysis treatments. *Nephrology (Carlton)* 2009; **14**: 455–461.
580. Hirsh J, Bauer KA, Donati MB, *et al*. Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest* 2008; **133**: 141S–159S.
581. Warkentin TE, Greinacher A, Koster A, *et al*. Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). *Chest* 2008; **133**: 340S–380S.
582. Baglin T, Barrowcliffe TW, Cohen A, *et al*. Guidelines on the use and monitoring of heparin. *Br J Haematol* 2006; **133**: 19–34.
583. Gray E, Mulloy B, Barrowcliffe TW. Heparin and low-molecular-weight heparin. *Thromb Haemostasis* 2008; **99**: 807–818.
584. Martel N, Lee J, Wells PS. Risk for heparin-induced thrombocytopenia with unfractionated and low-molecular-weight heparin thromboprophylaxis: a meta-analysis. *Blood* 2005; **106**: 2710–2715.
585. Davenport A, Tolwani A. Citrate anticoagulation for continuous renal replacement therapy (CRRT) in patients with acute kidney injury admitted to the intensive care unit. *NDT Plus* 2009; **2**: 439–447.
586. Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials. *J Am Soc Nephrol* 2004; **15**: 3192–3206.
587. European Best Practice Guidelines for Haemodialysis (Part 1). V. Chronic intermittent haemodialysis and prevention of clotting in the extracorporeal system. *Nephrol Dial Transplant* 2002; **17** (Suppl 7): 63–71.
588. Fischer KG. Essentials of anticoagulation in hemodialysis. *Hemodial Int* 2007; **11**: 178–189.
589. Ouseph R, Ward RA. Anticoagulation for intermittent hemodialysis. *Semin Dial* 2000; **13**: 181–187.
590. Lim W, Dentali F, Eikelboom JW, *et al*. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. *Ann Intern Med* 2006; **144**: 673–684.
591. Akizawa T, Koshikawa S, Ota K, *et al*. Nafamostat mesilate: a regional anticoagulant for hemodialysis in patients at high risk for bleeding. *Nephron* 1993; **64**: 376–381.
592. Matsuo T, Kario K, Nakao K, *et al*. Anticoagulation with nafamostat mesilate, a synthetic protease inhibitor, in hemodialysis patients with a bleeding risk. *Haemostasis* 1993; **23**: 135–141.
593. Yang JW, Han BG, Kim BR, *et al*. Superior outcome of nafamostat mesilate as an anticoagulant in patients undergoing maintenance hemodialysis with intracerebral hemorrhage. *Ren Fail* 2009; **31**: 668–675.
594. Maruyama H, Miyakawa Y, Gejyo E, *et al*. Anaphylactoid reaction induced by nafamostat mesilate in a hemodialysis patient. *Nephron* 1996; **74**: 468–469.
595. Muto S, Imai M, Asano Y. Mechanisms of hyperkalemia caused by nafamostat mesilate. *Gen Pharmacol* 1995; **26**: 1627–1632.
596. Okada H, Suzuki H, Deguchi N, *et al*. Agranulocytosis in a haemodialysed patient induced by a proteinase inhibitor, nafamostat mesilate. *Nephrol Dial Transplant* 1992; **7**: 980.
597. Novacek G, Kapiotis S, Jilma B, *et al*. Enhanced blood coagulation and enhanced fibrinolysis during hemodialysis with prostacyclin. *Thromb Res* 1997; **88**: 283–290.
598. Swartz RD, Flamenbaum W, Dubrow A, *et al*. Epoprostenol (PGI₂, prostacyclin) during high-risk hemodialysis: preventing further bleeding complications. *J Clin Pharmacol* 1988; **28**: 818–825.
599. Monchi M, Berghmans D, Ledoux D, *et al*. Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study. *Intensive Care Med* 2004; **30**: 260–265.
600. Kutsogiannis DJ, Gibney RT, Stollery D, *et al*. Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients. *Kidney Int* 2005; **67**: 2361–2367.
601. Betjes MG, van Oosterom D, van Agteren M, *et al*. Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding. *J Nephrol* 2007; **20**: 602–608.
- 601a. Hetzel GR, Schmitz, Wissing H, *et al*. Regional citrate versus systemic heparin for anticoagulation in critically ill patients on continuous venovenous haemofiltration: a prospective randomized multicentre trial. *Nephrol Dial Transplant* 2011; **26**: 232–239.
- 601b. Park JS, Kim GH, Kang CM, *et al*. Regional anticoagulation with citrate is superior to systemic anticoagulation with heparin in critically ill patients undergoing continuous venovenous hemodiafiltration. *Korean J Intern Med* 2011; **26**: 68–75.
602. Fealy N, Baldwin I, Johnstone M, *et al*. A pilot randomized controlled crossover study comparing regional heparinization to regional citrate anticoagulation for continuous venovenous hemofiltration. *Int J Artif Organs* 2007; **30**: 301–307.
603. Oudemans-van Straaten HM, Bosman RJ, Koopmans M, *et al*. Citrate anticoagulation for continuous venovenous hemofiltration. *Crit Care Med* 2009; **37**: 545–552.
604. Mehta RL, McDonald BR, Aguilar MM, *et al*. Regional citrate anticoagulation for continuous arteriovenous hemodialysis in critically ill patients. *Kidney Int* 1990; **38**: 976–981.
605. Morgera S, Scholle C, Voss G, *et al*. Metabolic complications during regional citrate anticoagulation in continuous venovenous hemodialysis: single-center experience. *Nephron Clin Pract* 2004; **97**: c131–136.
606. Thoenen M, Schmid ER, Binswanger U, *et al*. Regional citrate anticoagulation using a citrate-based substitution solution for continuous venovenous hemofiltration in cardiac surgery patients. *Wien Klin Wochenschr* 2002; **114**: 108–114.
607. Uchino S, Bellomo R, Morimatsu H, *et al*. Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators. *Intensive Care Med* 2007; **33**: 1563–1570.
608. Apsner R, Schwarzenhofer M, Derfler K, *et al*. Impairment of citrate metabolism in acute hepatic failure. *Wien Klin Wochenschr* 1997; **109**: 123–127.
609. Durao MS, Monte JC, Batista MC, *et al*. The use of regional citrate anticoagulation for continuous venovenous hemodiafiltration in acute kidney injury. *Crit Care Med* 2008; **36**: 3024–3029.
610. Kramer L, Bauer E, Joukhadar C, *et al*. Citrate pharmacokinetics and metabolism in cirrhotic and noncirrhotic critically ill patients. *Crit Care Med* 2003; **31**: 2450–2455.
611. Hetzel GR, Taskaya G, Sucker C, *et al*. Citrate plasma levels in patients under regional anticoagulation in continuous venovenous hemofiltration. *Am J Kidney Dis* 2006; **48**: 806–811.
612. Meier-Kriesche HU, Gitomer J, Finkel K, *et al*. Increased total to ionized calcium ratio during continuous venovenous hemodialysis with regional citrate anticoagulation. *Crit Care Med* 2001; **29**: 748–752.
613. Bakker AJ, Boerma EC, Keidel H, *et al*. Detection of citrate overdose in critically ill patients on citrate-anticoagulated venovenous haemofiltration: use of ionised and total/ionised calcium. *Clin Chem Lab Med* 2006; **44**: 962–966.
614. Davies HT, Leslie G, Pereira SM, *et al*. A randomized comparative crossover study to assess the effect on circuit life of varying pre-dilution volume associated with CVVH and CVVHDF. *Int J Artif Organs* 2008; **31**: 221–227.
615. Holt AW, Bierer P, Bersten AD, *et al*. Continuous renal replacement therapy in critically ill patients: monitoring circuit function. *Anaesth Intensive Care* 1996; **24**: 423–429.
616. Joannidis M, Kountchev J, Rauchenzauner M, *et al*. Enoxaparin vs. unfractionated heparin for anticoagulation during continuous veno-venous hemofiltration: a randomized controlled crossover study. *Intensive Care Med* 2007; **33**: 1571–1579.
617. Stefanidis I, Hagel J, Frank D, *et al*. Hemostatic alterations during continuous venovenous hemofiltration in acute renal failure. *Clin Nephrol* 1996; **46**: 199–205.
618. van de Wetering J, Westendorp RG, van der Hoeven JG, *et al*. Heparin use in continuous renal replacement procedures: the struggle between filter coagulation and patient hemorrhage. *J Am Soc Nephrol* 1996; **7**: 145–150.
619. Yang RL, Liu DW. [Clinical evaluation of hemofiltration without anticoagulation in critically ill patients at high risk of bleeding]. *Zhongguo Yi Xue Ke Xue Yuan Xue Bao* 2007; **29**: 651–655.
620. Reeves JH, Cumming AR, Gallagher L, *et al*. A controlled trial of low-molecular-weight heparin (dalteparin) versus unfractionated heparin as anticoagulant during continuous venovenous hemodialysis with filtration. *Crit Care Med* 1999; **27**: 2224–2228.
621. de Pont AC, Oudemans-van Straaten HM, Rozenendaal KJ, *et al*. Nadroparin versus dalteparin anticoagulation in high-volume, continuous venovenous hemofiltration: a double-blind, randomized, crossover study. *Crit Care Med* 2000; **28**: 421–425.
622. Birnbaum J, Spies CD, Klotz E, *et al*. Iloprost for additional anticoagulation in continuous renal replacement therapy—a pilot study. *Ren Fail* 2007; **29**: 271–277.
623. Kozek-Langenecker SA, Spiss CK, Gamsjager T, *et al*. Anticoagulation with prostaglandins and unfractionated heparin during continuous venovenous haemofiltration: a randomized controlled trial. *Wien Klin Wochenschr* 2002; **114**: 96–101.
624. Fabbri LP, Nucera M, Al Malyan M, *et al*. Regional anticoagulation and antiaggregation for CVVH in critically ill patients: a prospective, randomized, controlled pilot study. *Acta Anaesthesiol Scand* 2010; **54**: 92–97.

625. Fiaccadori E, Maggiore U, Rotelli C, *et al.* Continuous haemofiltration in acute renal failure with prostacyclin as the sole anti-haemostatic agent. *Intensive Care Med* 2002; **28**: 586–593.
626. Langenecker SA, Felfernig M, Werba A, *et al.* Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. *Crit Care Med* 1994; **22**: 1774–1781.
627. Biancofiore G, Esposito M, Bindi L, *et al.* Regional filter heparinization for continuous veno-venous hemofiltration in liver transplant recipients. *Minerva Anestesiol* 2003; **69**: 527–534; 534–528.
628. Kaplan AA, Petrillo R. Regional heparinization for continuous arterio-venous hemofiltration (CAVH). *ASAIO Trans* 1987; **33**: 312–315.
629. Carr JA, Silverman N. The heparin-protamine interaction. A review. *J Cardiovasc Surg (Torino)* 1999; **40**: 659–666.
630. Lasocki S, Piednoir P, Ajzenberg N, *et al.* Anti-PF4/heparin antibodies associated with repeated hemofiltration-filter clotting: a retrospective study. *Crit Care* 2008; **12**: R84.
631. Lo GK, Juhl D, Warkentin TE, *et al.* Evaluation of pretest clinical score (4 T's) for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. *J Thromb Haemost* 2006; **4**: 759–765.
632. O'Shea SI, Ortel TL, Kovalik EC. Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. *Semin Dial* 2003; **16**: 61–67.
633. Davenport A. Anticoagulation options for patients with heparin-induced thrombocytopenia requiring renal support in the intensive care unit. *Contrib Nephrol* 2007; **156**: 259–266.
634. Hursting MJ, Murray PT. Argatroban anticoagulation in renal dysfunction: a literature analysis. *Nephron Clin Pract* 2008; **109**: c80–94.
635. Link A, Girndt M, Selejan S, *et al.* Argatroban for anticoagulation in continuous renal replacement therapy. *Crit Care Med* 2009; **37**: 105–110.
636. Brophy PD, Somers MJ, Baum MA, *et al.* Multi-centre evaluation of anticoagulation in patients receiving continuous renal replacement therapy (CRRT). *Nephrol Dial Transplant* 2005; **20**: 1416–1421.
637. Bunchman TE, Maxvold NJ, Barnett J, *et al.* Pediatric hemofiltration: Normocarb dialysate solution with citrate anticoagulation. *Pediatr Nephrol* 2002; **17**: 150–154.
638. Bunchman TE, Maxvold NJ, Brophy PD. Pediatric convective hemofiltration: Normocarb replacement fluid and citrate anticoagulation. *Am J Kidney Dis* 2003; **42**: 1248–1252.
639. Klouche K, Amigues L, Deleuze S, *et al.* Complications, effects on dialysis dose, and survival of tunneled femoral dialysis catheters in acute renal failure. *Am J Kidney Dis* 2007; **49**: 99–108.
640. National Kidney Foundation. KDOQI clinical practice guidelines and clinical practice recommendations for 2006 updates: vascular access. *Am J Kidney Dis* 2006; **48**: S176–S307.
641. O'Grady NP, Alexander M, Dellinger EP, *et al.* Guidelines for the prevention of intravascular catheter-related infections. *Infect Control Hosp Epidemiol* 2002; **23**: 759–769.
642. Leblanc M, Fedak S, Mokris G, *et al.* Blood recirculation in temporary central catheters for acute hemodialysis. *Clin Nephrol* 1996; **45**: 315–319.
643. Little MA, Conlon PJ, Walshe JJ. Access recirculation in temporary hemodialysis catheters as measured by the saline dilution technique. *Am J Kidney Dis* 2000; **36**: 1135–1139.
644. Oliver MJ. Acute dialysis catheters. *Semin Dial* 2001; **14**: 432–435.
645. Twardowski ZJ. History of peritoneal access development. *Int J Artif Organs* 2006; **29**: 2–40.
646. Ronco C, Dell'Aquila R. Peritoneal access for acute peritoneal dialysis. In: Ronco C, Bellomo R, Kellum J (eds). *Critical Care Nephrology*, 2nd Edn. Saunders Elsevier: Philadelphia, PA, 2009, pp 1467–1471.
647. Asif A, Byers P, Vieira CF, *et al.* Peritoneoscopic placement of peritoneal dialysis catheter and bowel perforation: experience of an interventional nephrology program. *Am J Kidney Dis* 2003; **42**: 1270–1274.
648. Maya ID. Ultrasound/fluoroscopy-assisted placement of peritoneal dialysis catheters. *Semin Dial* 2007; **20**: 611–615.
649. Schmidt SC, Pohle C, Langrehr JM, *et al.* Laparoscopic-assisted placement of peritoneal dialysis catheters: implantation technique and results. *J Laparoendosc Adv Surg Tech A* 2007; **17**: 596–599.
650. Cimochoowski GE, Worley E, Rutherford WE, *et al.* Superiority of the internal jugular over the subclavian access for temporary dialysis. *Nephron* 1990; **54**: 154–161.
651. Schillinger F, Schillinger D, Montagnac R, *et al.* Post catheterisation vein stenosis in haemodialysis: comparative angiographic study of 50 subclavian and 50 internal jugular accesses. *Nephrol Dial Transplant* 1991; **6**: 722–724.
652. Oguzkurt L, Tercan F, Torun D, *et al.* Impact of short-term hemodialysis catheters on the central veins: a catheter venographic study. *Eur J Radiol* 2004; **52**: 293–299.
653. Taal MW, Chesterton LJ, McIntyre CW. Venography at insertion of tunnelled internal jugular vein dialysis catheters reveals significant occult stenosis. *Nephrol Dial Transplant* 2004; **19**: 1542–1545.
654. Agarwal AK, Patel BM, Haddad NJ. Central vein stenosis: a nephrologist's perspective. *Semin Dial* 2007; **20**: 53–62.
655. Puel V, Caudry M, Le Metayer P, *et al.* Superior vena cava thrombosis related to catheter malposition in cancer chemotherapy given through implanted ports. *Cancer* 1993; **72**: 2248–2252.
656. Yevzlin AS. Hemodialysis catheter-associated central venous stenosis. *Semin Dial* 2008; **21**: 522–527.
657. Pronovost P. Interventions to decrease catheter-related bloodstream infections in the ICU: the Keystone Intensive Care Unit Project. *Am J Infect Control* 2008; **36**: S171 e171–175.
658. Parienti JJ, Thirion M, Megarbane B, *et al.* Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized controlled trial. *JAMA* 2008; **299**: 2413–2422.
659. Hryszko T, Brzosko S, Mazerska M, *et al.* Risk factors of nontunneled noncuffed hemodialysis catheter malfunction. A prospective study. *Nephron Clin Pract* 2004; **96**: c43–47.
660. Liangos O, Rao M, Ruthazer R, *et al.* Factors associated with urea reduction ratio in acute renal failure. *Artif Organs* 2004; **28**: 1076–1081.
661. Naumovic RT, Jovanovic DB, Djukanovic LJ. Temporary vascular catheters for hemodialysis: a 3-year prospective study. *Int J Artif Organs* 2004; **27**: 848–854.
662. Oliver MJ, Edwards LJ, Treleven DJ, *et al.* Randomized study of temporary hemodialysis catheters. *Int J Artif Organs* 2002; **25**: 40–44.
663. Parienti JJ, Megarbane B, Fischer MO, *et al.* Catheter dysfunction and dialysis performance according to vascular access among 736 critically ill adults requiring renal replacement therapy: a randomized controlled study. *Crit Care Med* 2010; **38**: 1118–1125.
664. Marschall J, Mermel LA, Classen D, *et al.* Strategies to prevent central line-associated bloodstream infections in acute care hospitals. *Infect Control Hosp Epidemiol* 2008; **29** (Suppl 1): S22–30.
665. Pratt RJ, Pellowe CM, Wilson JA, *et al.* epic2: National evidence-based guidelines for preventing healthcare-associated infections in NHS hospitals in England. *J Hosp Infect* 2007; **65** (Suppl 1): S1–64.
666. Kusminsky RE. Complications of central venous catheterization. *J Am Coll Surg* 2007; **204**: 681–696.
667. McGee DC, Gould MK. Preventing complications of central venous catheterization. *N Engl J Med* 2003; **348**: 1123–1133.
668. Hind D, Calvert N, McWilliams R, *et al.* Ultrasonic locating devices for central venous cannulation: meta-analysis. *BMJ* 2003; **327**: 361.
669. Randolph AG, Cook DJ, Gonzales CA, *et al.* Ultrasound guidance for placement of central venous catheters: a meta-analysis of the literature. *Crit Care Med* 1996; **24**: 2053–2058.
670. Karakitsos D, Labropoulos N, De Groot E, *et al.* Real-time ultrasound-guided catheterisation of the internal jugular vein: a prospective comparison with the landmark technique in critical care patients. *Crit Care* 2006; **10**: R162.
671. Leung J, Duffy M, Finckh A. Real-time ultrasonographically-guided internal jugular vein catheterization in the emergency department increases success rates and reduces complications: a randomized, prospective study. *Ann Emerg Med* 2006; **48**: 540–547.
672. Bansal R, Agarwal SK, Tiwari SC, *et al.* A prospective randomized study to compare ultrasound-guided with nonultrasound-guided double lumen internal jugular catheter insertion as a temporary hemodialysis access. *Ren Fail* 2005; **27**: 561–564.
673. Farrell J, Gellens M. Ultrasound-guided cannulation versus the landmark-guided technique for acute haemodialysis access. *Nephrol Dial Transplant* 1997; **12**: 1234–1237.
674. Gallieni M. Central vein catheterization of dialysis patients with real time ultrasound guidance. *J Vasc Access* 2000; **1**: 10–14.
675. Kwon TH, Kim YL, Cho DK. Ultrasound-guided cannulation of the femoral vein for acute haemodialysis access. *Nephrol Dial Transplant* 1997; **12**: 1009–1012.
676. Lin BS, Huang TP, Tang GJ, *et al.* Ultrasound-guided cannulation of the internal jugular vein for dialysis vascular access in uremic patients. *Nephron* 1998; **78**: 423–428.
677. Nadig C, Leidig M, Schmiedeke T, *et al.* The use of ultrasound for the placement of dialysis catheters. *Nephrol Dial Transplant* 1998; **13**: 978–981.
678. Zollo A, Cavatorta F, Galli S. Ultrasound-guided cannulation of the femoral vein for acute hemodialysis access with silicone catheters. *J Vasc Access* 2001; **2**: 56–59.
679. Schummer W, Sakr Y, Schummer C. Towards optimal central venous catheter tip position. In: Vincent J-L (ed). *Intensive Care Medicine*. Springer Verlag: Berlin, Germany, 2008, pp 581–590.
680. Vesely TM. Central venous catheter tip position: a continuing controversy. *J Vasc Interv Radiol* 2003; **14**: 527–534.

681. Hsu JH, Wang CK, Chu KS, *et al.* Comparison of radiographic landmarks and the echocardiographic SVC/RA junction in the positioning of long-term central venous catheters. *Acta Anaesthesiol Scand* 2006; **50**: 731–735.
682. James MT, Conley J, Tonelli M, *et al.* Meta-analysis: antibiotics for prophylaxis against hemodialysis catheter-related infections. *Ann Intern Med* 2008; **148**: 596–605.
683. Jaffer Y, Selby NM, Taal MW, *et al.* A meta-analysis of hemodialysis catheter locking solutions in the prevention of catheter-related infection. *Am J Kidney Dis* 2008; **51**: 233–241.
684. Labriola L, Crott R, Jadoul M. Preventing haemodialysis catheter-related bacteraemia with an antimicrobial lock solution: a meta-analysis of prospective randomized trials. *Nephrol Dial Transplant* 2008; **23**: 1666–1672.
685. Yahav D, Rozen-Zvi B, Gafter-Gvili A, *et al.* Antimicrobial lock solutions for the prevention of infections associated with intravascular catheters in patients undergoing hemodialysis: systematic review and meta-analysis of randomized, controlled trials. *Clin Infect Dis* 2008; **47**: 83–93.
686. Hackbarth R, Bunchman TE, Chua AN, *et al.* The effect of vascular access location and size on circuit survival in pediatric continuous renal replacement therapy: a report from the PPCRRT registry. *Int J Artif Organs* 2007; **30**: 1116–1121.
687. Bunchman TE, Brophy PD, Goldstein SL. Technical considerations for renal replacement therapy in children. *Semin Nephrol* 2008; **28**: 488–492.
688. McDonald SP, Craig JC. Long-term survival of children with end-stage renal disease. *N Engl J Med* 2004; **350**: 2654–2662.
689. Chadha V, Warady BA, Blowey DL, *et al.* Tenckhoff catheters prove superior to cook catheters in pediatric acute peritoneal dialysis. *Am J Kidney Dis* 2000; **35**: 1111–1116.
690. Auron A, Warady BA, Simon S, *et al.* Use of the multipurpose drainage catheter for the provision of acute peritoneal dialysis in infants and children. *Am J Kidney Dis* 2007; **49**: 650–655.
691. Modi GK, Pereira BJ, Jaber BL. Hemodialysis in acute renal failure: does the membrane matter? *Semin Dial* 2001; **14**: 318–321.
692. Canivet E, Lavaud S, Wong T, *et al.* Cuprophane but not synthetic membrane induces increases in serum tumor necrosis factor- α levels during hemodialysis. *Am J Kidney Dis* 1994; **23**: 41–46.
693. Marchant A, Tielemans C, Husson C, *et al.* Cuprophane haemodialysis induces upregulation of LPS receptor (CD14) on monocytes: role of complement activation. *Nephrol Dial Transplant* 1996; **11**: 657–662.
694. Patarca R, Perez G, Gonzalez A, *et al.* Comprehensive evaluation of acute immunological changes induced by cuprophane and polysulfone membranes in a patient on chronic hemodialysis. *Am J Nephrol* 1992; **12**: 274–278.
695. Puentes F, Pons H, Rodriguez-Iturbe B. Hemodialysis with cuprophane membranes is associated with a reduction in peripheral blood mononuclear cells expressing VLA-4 cell adhesion molecule. *Clin Nephrol* 1994; **42**: 278–279.
696. Schaefer RM, Huber L, Gilge U, *et al.* Clinical evaluation of a new high-flux cellulose acetate membrane. *Int J Artif Organs* 1989; **12**: 85–90.
697. Walker RJ, Sutherland WH, De Jong SA. Effect of changing from a cellulose acetate to a polysulfone dialysis membrane on protein oxidation and inflammation markers. *Clin Nephrol* 2004; **61**: 198–206.
698. Itoh S, Susuki C, Tsuji T. Platelet activation through interaction with hemodialysis membranes induces neutrophils to produce reactive oxygen species. *J Biomed Mater Res A* 2006; **77**: 294–303.
699. Hakim RM, Schafer AI. Hemodialysis-associated platelet activation and thrombocytopenia. *Am J Med* 1985; **78**: 575–580.
700. Sirolli V, Strizzi L, Di Stante S, *et al.* Platelet activation and platelet-erythrocyte aggregates in end-stage renal disease patients on hemodialysis. *Thromb Haemost* 2001; **86**: 834–839.
701. Takeshita K, Susuki C, Itoh S, *et al.* Preventive effect of alpha-tocopherol and glycyrrhizin against platelet-neutrophil complex formation induced by hemodialysis membranes. *Int J Artif Organs* 2009; **32**: 282–290.
702. Alonso A, Lau J, Jaber BL. Biocompatible hemodialysis membranes for acute renal failure. *Cochrane Database Syst Rev* 2008; CD005283.
703. Brophy PD, Mottes TA, Kudelka TL, *et al.* AN-69 membrane reactions are pH-dependent and preventable. *Am J Kidney Dis* 2001; **38**: 173–178.
704. Hackbarth RM, Eding D, Gianoli Smith C, *et al.* Zero balance ultrafiltration (Z-BUF) in blood-primed CRRT circuits achieves electrolyte and acid-base homeostasis prior to patient connection. *Pediatr Nephrol* 2005; **20**: 1328–1333.
705. Pasko DA, Mottes TA, Mueller BA. Pre dialysis of blood prime in continuous hemodialysis normalizes pH and electrolytes. *Pediatr Nephrol* 2003; **18**: 1177–1183.
706. Perez-Garcia R, Galan A, Garcia Vinuesa M, *et al.* Anaphylactoid reactions during hemodialysis on AN69 membranes: role of ACE inhibitors and back-filtration. *Nephron* 1992; **61**: 123.
707. Petrie JJ, Campbell Y, Hawley CM, *et al.* Anaphylactoid reactions in patients on hemodiafiltration with AN69 membranes whilst receiving ACE inhibitors. *Clin Nephrol* 1991; **36**: 264–265.
708. Tielemans C, Madhoun P, Lenaers M, *et al.* Anaphylactoid reactions during hemodialysis on AN69 membranes in patients receiving ACE inhibitors. *Kidney Int* 1990; **38**: 982–984.
709. Desormeaux A, Moreau ME, Lepage Y, *et al.* The effect of electronegativity and angiotensin-converting enzyme inhibition on the kinin-forming capacity of polyacrylonitrile dialysis membranes. *Biomaterials* 2008; **29**: 1139–1146.
710. RENAL Study Investigators. Renal replacement therapy for acute kidney injury in Australian and New Zealand intensive care units: a practice survey. *Crit Care Resusc* 2008; **10**: 225–230.
711. Gatward JJ, Gibbon GJ, Wrathall G, *et al.* Renal replacement therapy for acute renal failure: a survey of practice in adult intensive care units in the United Kingdom. *Anaesthesia* 2008; **63**: 959–966.
712. Langford S, Slivar S, Tucker SM, *et al.* Exploring CRRT practices in ICU: a survey of Canadian hospitals. *Dynamics* 2008; **19**: 18–23.
713. Rabindranath K, Adams J, Macleod AM, *et al.* Intermittent versus continuous renal replacement therapy for acute renal failure in adults. *Cochrane Database Syst Rev* 2007; CD003773.
714. Bagshaw SM, Berthiaume LR, Delaney A, *et al.* Continuous versus intermittent renal replacement therapy for critically ill patients with acute kidney injury: a meta-analysis. *Crit Care Med* 2008; **36**: 610–617.
715. Pannu N, Klarenbach S, Wiebe N, *et al.* Renal replacement therapy in patients with acute renal failure: a systematic review. *JAMA* 2008; **299**: 793–805.
716. Lins RL, Elseviers MM, Van der Niepen P, *et al.* Intermittent versus continuous renal replacement therapy for acute kidney injury patients admitted to the intensive care unit: results of a randomized clinical trial. *Nephrol Dial Transplant* 2009; **24**: 512–518.
717. Farese S, Jakob SM, Kalicki R, *et al.* Treatment of acute renal failure in the intensive care unit: lower costs by intermittent dialysis than continuous venovenous hemodiafiltration. *Artif Organs* 2009; **33**: 634–640.
718. Klarenbach S, Manns B, Pannu N, *et al.* Economic evaluation of continuous renal replacement therapy in acute renal failure. *Int J Technol Assess Health Care* 2009; **25**: 331–338.
719. Srisawat N, Lawsin L, Uchino S, *et al.* Cost of acute renal replacement therapy in the intensive care unit: results from The Beginning and Ending Supportive Therapy for the Kidney (BEST Kidney) study. *Crit Care* 2010; **14**: R46.
720. Bell M, Granath F, Schon S, *et al.* Continuous renal replacement therapy is associated with less chronic renal failure than intermittent haemodialysis after acute renal failure. *Intensive Care Med* 2007; **33**: 773–780.
721. Jacka MJ, Ivancinova X, Gibney RT. Continuous renal replacement therapy improves renal recovery from acute renal failure. *Can J Anaesth* 2005; **52**: 327–332.
722. Uchino S, Bellomo R, Kellum JA, *et al.* Patient and kidney survival by dialysis modality in critically ill patients with acute kidney injury. *Int J Artif Organs* 2007; **30**: 281–292.
723. Kielstein JT, Schiffer M, Hafer C. Back to the future: extended dialysis for treatment of acute kidney injury in the intensive care unit. *J Nephrol* 2010; **23**: 494–501.
724. Kielstein JT, Kretschmer U, Ernst T, *et al.* Efficacy and cardiovascular tolerability of extended dialysis in critically ill patients: a randomized controlled study. *Am J Kidney Dis* 2004; **43**: 342–349.
725. Baldwin I, Bellomo R, Naka T, *et al.* A pilot randomized controlled comparison of extended daily dialysis with filtration and continuous venovenous hemofiltration: fluid removal and hemodynamics. *Int J Artif Organs* 2007; **30**: 1083–1089.
726. Baldwin I, Naka T, Koch B, *et al.* A pilot randomised controlled comparison of continuous veno-venous haemofiltration and extended daily dialysis with filtration: effect on small solutes and acid-base balance. *Intensive Care Med* 2007; **33**: 830–835.
727. Marshall MR, Creamer JM, Foster M, *et al.* Mortality rate comparison after switching from continuous to prolonged intermittent renal replacement for acute kidney injury in three intensive care units from different countries. *Nephrol Dial Transplant* 2011; **26**: 2169–2175.
728. Fieghen HE, Friedrich JO, Burns KE, *et al.* The hemodynamic tolerability and feasibility of sustained low efficiency dialysis in the management of critically ill patients with acute kidney injury. *BMC Nephrol* 2010; **11**: 32.
729. Davenport A. Continuous renal replacement therapies in patients with acute neurological injury. *Semin Dial* 2009; **22**: 165–168.
730. Bagshaw SM, Peets AD, Hameed M, *et al.* Dialysis Disequilibrium Syndrome: brain death following hemodialysis for metabolic acidosis and acute renal failure—a case report. *BMC Nephrol* 2004; **5**: 9.
731. Lin CM, Lin JW, Tsai JT, *et al.* Intracranial pressure fluctuation during hemodialysis in renal failure patients with intracranial hemorrhage. *Acta Neurochir Suppl* 2008; **101**: 141–144.

732. Ronco C, Bellomo R, Brendolan A, *et al.* Brain density changes during renal replacement in critically ill patients with acute renal failure. Continuous hemofiltration versus intermittent hemodialysis. *J Nephrol* 1999; **12**: 173–178.
733. Paganini EP, Sandy D, Moreno L, *et al.* The effect of sodium and ultrafiltration modelling on plasma volume changes and haemodynamic stability in intensive care patients receiving haemodialysis for acute renal failure: a prospective, stratified, randomized, cross-over study. *Nephrol Dial Transplant* 1996; **11** (Suppl 8): 32–37.
734. Schortgen F, Soubrier N, Delclaux C, *et al.* Hemodynamic tolerance of intermittent hemodialysis in critically ill patients: usefulness of practice guidelines. *Am J Respir Crit Care Med* 2000; **162**: 197–202.
735. Bargman JM. New technologies in peritoneal dialysis. *Clin J Am Soc Nephrol* 2007; **2**: 576–580.
736. Chionh CY, Soni S, Cruz DN, *et al.* Peritoneal dialysis for acute kidney injury: techniques and dose. *Contrib Nephrol* 2009; **163**: 278–284.
737. Ronco C, Amerling R. Continuous flow peritoneal dialysis: current state-of-the-art and obstacles to further development. *Contrib Nephrol* 2006; **150**: 310–320.
738. Phu NH, Hien TT, Mai NT, *et al.* Hemofiltration and peritoneal dialysis in infection-associated acute renal failure in Vietnam. *N Engl J Med* 2002; **347**: 895–902.
739. Gabriel DP, Caramori JT, Martim LC, *et al.* High volume peritoneal dialysis vs daily hemodialysis: a randomized, controlled trial in patients with acute kidney injury. *Kidney Int Suppl* 2008; S87–93.
740. Vachvanichsanong P, Dissaneewate P, Lim A, *et al.* Childhood acute renal failure: 22-year experience in a university hospital in southern Thailand. *Pediatrics* 2006; **118**: e786–791.
741. Bailey D, Phan V, Litalien C, *et al.* Risk factors of acute renal failure in critically ill children: A prospective descriptive epidemiological study. *Pediatr Crit Care Med* 2007; **8**: 29–35.
742. Bunchman TE, Maxvold NJ, Kershaw DB, *et al.* Continuous venovenous hemodiafiltration in infants and children. *Am J Kidney Dis* 1995; **25**: 17–21.
743. Sadowski RH, Harmon WE, Jabs K. Acute hemodialysis of infants weighing less than five kilograms. *Kidney Int* 1994; **45**: 903–906.
744. Symons JM, Brophy PD, Gregory MJ, *et al.* Continuous renal replacement therapy in children up to 10 kg. *Am J Kidney Dis* 2003; **41**: 984–989.
745. Warady BA, Bunchman T. Dialysis therapy for children with acute renal failure: survey results. *Pediatr Nephrol* 2000; **15**: 11–13.
746. Bunchman TE, McBryde KD, Mottes TE, *et al.* Pediatric acute renal failure: outcome by modality and disease. *Pediatr Nephrol* 2001; **16**: 1067–1071.
747. Flores FX, Brophy PD, Symons JM, *et al.* Continuous renal replacement therapy (CRRT) after stem cell transplantation. A report from the prospective pediatric CRRT Registry Group. *Pediatr Nephrol* 2008; **23**: 625–630.
748. Noris M, Todeschini M, Casiraghi F, *et al.* Effect of acetate, bicarbonate dialysis, and acetate-free biofiltration on nitric oxide synthesis: implications for dialysis hypotension. *Am J Kidney Dis* 1998; **32**: 115–124.
749. Levraut J, Ichai C, Petit I, *et al.* Low exogenous lactate clearance as an early predictor of mortality in normolactatemic critically ill septic patients. *Crit Care Med* 2003; **31**: 705–710.
750. Veech RL. The untoward effects of the anions of dialysis fluids. *Kidney Int* 1988; **34**: 587–597.
751. Barenbrock M, Hausberg M, Matzkies F, *et al.* Effects of bicarbonate- and lactate-buffered replacement fluids on cardiovascular outcome in CVVH patients. *Kidney Int* 2000; **58**: 1751–1757.
752. McLean AG, Davenport A, Cox D, *et al.* Effects of lactate-buffered and lactate-free dialysate in CAVHD patients with and without liver dysfunction. *Kidney Int* 2000; **58**: 1765–1772.
753. Thomas AN, Guy JM, Kishen R, *et al.* Comparison of lactate and bicarbonate buffered haemofiltration fluids: use in critically ill patients. *Nephrol Dial Transplant* 1997; **12**: 1212–1217.
754. Tan HK, Uchino S, Bellomo R. The acid-base effects of continuous hemofiltration with lactate or bicarbonate buffered replacement fluids. *Int J Artif Organs* 2003; **26**: 477–483.
755. Zimmerman D, Cotman P, Ting R, *et al.* Continuous veno-venous haemodialysis with a novel bicarbonate dialysis solution: prospective cross-over comparison with a lactate buffered solution. *Nephrol Dial Transplant* 1999; **14**: 2387–2391.
756. Holloway P, Benham S, St John A. The value of blood lactate measurements in ICU: an evaluation of the role in the management of patients on haemofiltration. *Clin Chim Acta* 2001; **307**: 9–13.
757. Ledebro I. On-line preparation of solutions for dialysis: practical aspects versus safety and regulations. *J Am Soc Nephrol* 2002; **13** (Suppl 1): S78–83.
758. Marshall MR, Ma T, Galler D, *et al.* Sustained low-efficiency daily diafiltration (SLEDD-f) for critically ill patients requiring renal replacement therapy: towards an adequate therapy. *Nephrol Dial Transplant* 2004; **19**: 877–884.
759. Ronco C. Backfiltration in clinical dialysis: nature of the phenomenon, mechanisms and possible solutions. *Int J Artif Organs* 1990; **13**: 11–21.
760. Kanagasundaram NS, Larive AB, Paganini EP. A preliminary survey of bacterial contamination of the dialysate circuit in continuous veno-venous hemodialysis. *Clin Nephrol* 2003; **59**: 47–55.
761. Moore I, Bhat R, Hoenich NA, *et al.* A microbiological survey of bicarbonate-based replacement circuits in continuous veno-venous hemofiltration. *Crit Care Med* 2009; **37**: 496–500.
762. Ward RA. Worldwide guidelines for the preparation and quality management of dialysis fluid and their implementation. *Blood Purif* 2009; **27** (Suppl 1): 2–4.
763. Association for the Advancement of Medical Instrumentation. *Water for Hemodialysis and Related Therapies*. ANSI/AAMI/ISO 13959:2009. AAMI: Arlington, VA, 2010.
764. Association for the Advancement of Medical Instrumentation. *Concentrates for Hemodialysis and Related Therapies*. ANSI/AAMI/ISO 13958:2009. AAMI: Arlington, VA, 2011.
765. Association for the Advancement of Medical Instrumentation. *Quality of Dialysis Fluid for Hemodialysis and Related Therapies*. ANSI/AAMI/ISO 11663:2009. AAMI: Arlington, VA, 2010.
- 765a. European best practice guidelines for haemodialysis (Part 1). Section IV: Dialysis fluid purity. *Nephrol Dial Transplant* 2002; **17** (Suppl): 45–62.
766. Kolff WJ. First clinical experience with the artificial kidney. *Ann Intern Med* 1965; **62**: 608–619.
767. Davenport A, Bouman C, Kirpalani A, *et al.* Delivery of renal replacement therapy in acute kidney injury: what are the key issues? *Clin J Am Soc Nephrol* 2008; **3**: 869–875.
768. Faulhaber-Walter R, Hafer C, Jahr N, *et al.* The Hannover Dialysis Outcome study: comparison of standard versus intensified extended dialysis for treatment of patients with acute kidney injury in the intensive care unit. *Nephrol Dial Transplant* 2009; **24**: 2179–2186.
769. Ronco C, Bellomo R, Homel P, *et al.* Effects of different doses in continuous veno-venous haemofiltration on outcomes of acute renal failure: a prospective randomised trial. *Lancet* 2000; **356**: 26–30.
770. Saudan P, Niederberger M, De Seigneux S, *et al.* Adding a dialysis dose to continuous hemofiltration increases survival in patients with acute renal failure. *Kidney Int* 2006; **70**: 1312–1317.
771. Schiff H, Lang SM, Fischer R. Daily hemodialysis and the outcome of acute renal failure. *N Engl J Med* 2002; **346**: 305–310.
772. Tolwani AJ, Campbell RC, Stofan BS, *et al.* Standard versus high-dose CVVHDF for ICU-related acute renal failure. *J Am Soc Nephrol* 2008; **19**: 1233–1238.
773. Paganini EP, Tapolyai M, Goormastic M, *et al.* Establishing a dialysis therapy/patient outcome link in intensive care unit acute dialysis for patients with acute renal failure. *Am J Kidney Dis* 1996; **28** (Suppl 3): S81–S89.
774. Ricci Z, Ronco C, D’Amico G, *et al.* Practice patterns in the management of acute renal failure in the critically ill patient: an international survey. *Nephrol Dial Transplant* 2006; **21**: 690–696.
775. Ikizler TA, Sezer MT, Flakoll PJ, *et al.* Urea space and total body water measurements by stable isotopes in patients with acute renal failure. *Kidney Int* 2004; **65**: 725–732.
776. Evanson JA, Ikizler TA, Wingard R, *et al.* Measurement of the delivery of dialysis in acute renal failure. *Kidney Int* 1999; **55**: 1501–1508.
777. Evanson JA, Himmelfarb J, Wingard R, *et al.* Prescribed versus delivered dialysis in acute renal failure patients. *Am J Kidney Dis* 1998; **32**: 731–738.
778. Schiff H. Disease severity adversely affects delivery of dialysis in acute renal failure. *Nephron Clin Pract* 2007; **107**: c163–169.
779. Gotch FA, Sargent JA. A mechanistic analysis of the National Cooperative Dialysis Study (NCDS). *Kidney Int* 1985; **28**: 526–534.
780. Held PJ, Port FK, Wolfe RA, *et al.* The dose of hemodialysis and patient mortality. *Kidney Int* 1996; **50**: 550–556.
781. Eknoyan G, Beck GJ, Cheung AK, *et al.* Effect of dialysis dose and membrane flux in maintenance hemodialysis. *N Engl J Med* 2002; **347**: 2010–2019.
782. Venkataraman R, Kellum JA, Palevsky P. Dosing patterns for continuous renal replacement therapy at a large academic medical center in the United States. *J Crit Care* 2002; **17**: 246–250.
783. Boussekey N, Chiche A, Faure K, *et al.* A pilot randomized study comparing high and low volume hemofiltration on vasopressor use in septic shock. *Intensive Care Med* 2008; **34**: 1646–1653.